Humanized antibodies to tnf-like ligand 1a (TL1a) and uses thereof

Abstract

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn’s Disease (CD) and ulcerative colitis (UC).

Description

HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USESTHEREOFCROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Application No.62 / 925,736, filed October 24, 2019, which application is incorporated herein by reference in its entirety.SEQUENCE LISTING

[0002] The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on October 23, 2020, is named 56884-767_601_SL.txt and is 376,991 bytes in size.BACKGROUND

[0003] Inflammatory bowel disease (IBD) refers to a collection of intestinal disorders causing inflammatory conditions in the gastrointestinal tract. The primary types of IBD are ulcerative colitis (UC) and Crohn’s Disease (CD). These diseases are prevalent, with about 1.86 million people diagnosed globally with UC, and about 1.3 million people diagnosed globally with CD. Severe forms of IBD may be characterized by intestinal fibrosis, which is the accumulation of scar tissue in the intestinal wall. There are a limited number of therapies available for IBD patients, and the development of new therapeutics has been hampered by sub-optimal results in clinical trials. Furthermore, a significant number of patients experience a lack of response or a loss of response to existing anti-inflammatory therapies. While the patient is treated with this ineffective anti-inflammatory therapy, the disease worsens. Currently the only treatment for patients that do not respond to first line therapies is surgery, in the form of structureplasty (reshaping of the intestine) or resection (removal of the intestine). Surgical treatments for IBD are invasive, causing post-operative risks for an estimated one-third of patients undergoing surgery, such as anastomotic leak, infection, and bleeding.

[0004] The pathogenesis of IBD is thought to involve an uncontrolled immune response that may be triggered by certain environmental factors in a genetically susceptible host. The heterogeneity of disease pathogenesis and clinical course, combined with the variable response to treatment and its associated side effects, suggests a targeted therapeutic approach to treating these diseases is a desirable treatment strategy. Yet there are very few targetedtherapies available to IBD patients, especially those patients who may be non-responsive to existing IBD therapies. Accordingly, there is a need for novel therapeutics to treat IBD that specifically target IBD pathogenesis.SUMMARY

[0005] The present disclosure provides tumor necrosis factor ligand 1 A (TL1 A) binding antibodies for the treatment of IBD, including severe forms of IBD characterized by intestinal fibrosis. In various aspects, antibodies described herein possess features useful for therapeutic application such as low immunogenicity, and / or features that facilitate antibody manufacture, such as high percentage of monomeric fraction as measured by size-exclusion chromatography, and / or high expression.

[0006] In one aspect, provided herein, is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable framework region comprising a human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework, and a light chain variable framework region comprising a human IGKV3-20 framework or a modified human IGKV3-20 framework; wherein the heavy chain variable framework region and the light chain variable framework region collectively comprise less than 9 amino acid modifications from the human IGHV1 -46*02 framework and the human IGKV3-20 framework. In some embodiments, the amino acid modification comprises: (a) a modification at amino acid position 47 in the heavy chain variable region; (b) a modification at amino acid position 45 in the heavy chain variable region; (c) a modification at amino acid position 55 in the heavy chain variable region; (d) a modification at amino acid position 78 in the heavy chain variable region; (e) a modification at amino acid position 80 in the heavy chain variable region; (f) a modification at amino acid position 82 in the heavy chain variable region; (g) a modification at amino acid position 89 in the heavy chain variable region; or (h) a modification at amino acid position 91 in the heavy chain variable region; per Kabat numbering; or a combination of two or more modifications selected from (a) to (h). In some embodiments, (a) the amino acid modification is at position 47 in the heavy chain variable region, and the amino acid at position 47 is R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (b) the amino acid modification is at position 45 in the heavy chain variable region, and the amino acid at position 45 is A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (c) the amino acid modification is at position 55 in the heavy chain variable region, and the amino acid at position 55 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; (d) the amino acid modification is at position 78 in the heavy chain variable region, and theamino acid at position 78 is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y; (e) the amino acid modification is at position 80 in the heavy chain variable region, and the amino acid at position 80 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; (f) the amino acid modification is at position 82 in the heavy chain variable region, and the amino acid at position 82 is A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (g) the amino acid modification is at position 89 in the heavy chain variable region, and the amino acid at position 89 is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y; or (h) the amino acid modification is at position 91 in the heavy chain variable region, and the amino acid at position 91 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; or a combination of two or more modifications selected from (a) to (h). In some embodiments, the amino acid modifications comprise one or more of: A47R, R45K, M55I, V78A, M80I, R82T, V89A, M91L in the heavy chain variable region, per Rabat numbering. In some embodiments, the amino acid modification comprises: (a) a modification at amino acid position 54 in the light chain variable region; and / or (b) a modification at amino acid position 55 in the light chain variable region; per Rabat numbering. In some embodiments, (a) the amino acid modification is at position 54 of the light chain variable region, and the amino acid at position 54 is A, R, N, D, C, Q, E, G, H, I, R, M, F, P, S, T, W, Y, or V; and / or (b) the amino acid modification is at position 55 of the light chain variable region, and the amino acid at position 55 is A, R, N, D, C, Q, E, G, H, I, R, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid modifications comprise L54P and / or L55W in the light chain variable region, per Rabat numbering. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR1 as set forth by SEQ ID NO: 1, a heavy chain CDR2 as set forth by any one of SEQ ID NOS: 2-5, a heavy chain CDR3 as set forth by any one of SEQ ID NOS: 6-9, a light chain CDR1 as set forth by SEQ ID NO: 10, a light chain CDR2 as set forth by SEQ ID NO: 11, and a light chain CDR3 as set forth by any one of SEQ ID NOS: 12-15. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR1 as set forth by SEQ ID NO: 1, a heavy chain CDR2 as set forth by SEQ ID NO: 2, a heavy chain CDR3 as set forth by SEQ ID NO: 6, a light chain CDR1 as set forth by SEQ ID NO: 10, a light chain CDR2 as set forth by SEQ ID NO: 11, and a light chain CDR3 as set forth by SEQ ID NO: 12. In some embodiments, the antibody or antigen binding fragment comprises comprising a heavy chain framework (FR) 1 as set forth by SEQ ID NO: 304, a heavy chain FR2 as set forth by SEQ ID NO: 305 or SEQ ID NO: 313, a heavy chain FR3 as set forth by any one of SEQ ID NOS: 306, 307, 314, or 315, a heavy chain FR4 as set forth by SEQ ID NO: 308, a light chain FR1 as set forth by SEQ ID NO: 309, a light chain FR2 as set forth bySEQ ID NO: 310, a light chain FR3 as set forth by SEQ ID NO: 311, or a light chain FR4 as set forth by SEQ ID NO: 312, or a combination thereof. In some embodiments, the antibody or antigen binding fragment comprises a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A,(i) 327Q or 327T, (j) 329 A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238A,238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r)264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270 A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 33 OR, (hh) 339E or 339L, (ii) 3431 or 343 V, (jj) 373 A, 373G, or 373 S, (kk) 376E,376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of two or more selected from (a) - (uu), per Rabat numbering. In some embodiments, the antibody or antigen binding fragment comprises a human IgG4 Fc region. In some embodiments, the antibody or antigen binding fragment comprises a Fc region comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362. In some embodiments, the antibody or antigen binding fragment comprises at least about 80% monomeric fraction as determined by size exclusion chromatography. In some embodiments, the antibody or antigen binding fragment expresses at least about 20 ug / ml total antibody, optionally about 20 ug / ml and 70 ug / mL total antibody.

[0007] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising an amino acid sequence at least 96% identical to SEQ ID NO: 104, and a light chain variable domain comprising an amino acid sequence at least 97% identical to SEQ ID NO: 201. In some embodiments, the heavy chain variable domaincomprises an amino acid sequence at least 97% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises an amino acid sequence at least 98% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises an amino acid sequence at least 99% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises SEQ ID NO: 104. In some embodiments, the light chain variable domain comprises an amino acid sequence at least 98% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises an amino acid sequence at least about 99% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises SEQ ID NO: 201.

[0008] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising an amino acid sequence at least about 99% identical to any one of SEQ ID NOS: 101-135, and a light chain variable domain comprising an amino acid sequence at least about 99% identical to any one of SEQ ID NOS: 201-206.

[0009] In some embodiments, antibodies or antigen binding fragments described herein comprise a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j)329 A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293 S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440 A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu)L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of two or more selected from (a) - (uu), per Rabat numbering. In some embodiments, antibodies orantigen binding fragments described herein comprise a human IgG4 Fc region. In some embodiments, antibodies or antigen binding fragments described herein comprise a Fc region comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362. In some embodiments, antibodies or antigen binding fragments described herein comprise at least about 80% monomeric fraction as determined by size exclusion chromatography. In some embodiments, antibodies or antigen binding fragments described herein express at least about 20 ug / ml total antibody, optionally about 20 ug / ml and 70 ug / mL total antibody.

[0010] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable region comprising: (a) an HCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 1; (b) an HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 2-5; and (c) an HCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 6-9; and the light chain variable region comprises: (d) an LCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 10; (e) an LCDR2 comprising an amino acid sequence set forth by SEQ ID NO: 11; (f) an LCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 12-15; and a fragment crystallizable (Fc) region comprising reduced antibody- dependent cell-mediated cytotoxicity (ADCC) function as compared to human IgGl and / or reduced complement-dependent cytotoxicity (CDC) as compared to human IgGl . In some embodiments, the human IgGl comprises SEQ ID NO: 320. In some embodiments, the ADCC function of the Fc region comprising reduced ADCC is at least about 50% reduced as compared to human IgGl. In some embodiments, the CDC function of the Fc region comprising reduced CDC is at least about 50% reduced as compared to human IgGl. In some embodiments, the Fc region comprises a human IgGl comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235 S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329 A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G,238H, 2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q,(w) 270 A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293 S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 311S, (ee) 316F, (ff) 328V, (gg) 330R,(hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G,(rr) 439E, 439H, or 439Q, (ss) 440 A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A,L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331A or P331S, or (nnn) any combination of (a) - (uu), per Rabat numbering. In some embodiments, the antibody or antigen binding fragment comprises a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P, (b) S228P and L235E, or (c) S228P, F234A, and L235A, per Rabat numbering. In some embodiments, the antibody or antigen binding fragment comprises a human IgG2 Fc region; IgG2-IgG4 cross-subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2o). In some embodiments, the Fc region comprises a human IgGl with a substitution selected from 329A, 329G, 329Y, 33 IS, 236F,236R, 238 A, 238E, 238G, 238H, 2381, 238V, 238W, 238 Y, 248 A, 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, 254V, 264S, 265H, 265R, 265 S, 265 Y, 265 A, 267G, 267H, 2671, 267R, 4341, 438G, 439E, 439H, 439Q, 440A, 440D, 440E, 440F, 440M, 440T, and 440V, per Rabat numbering. In some embodiments, the antibody or antigen binding fragment comprises a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362. In some embodiments, the HCDR1 comprises SEQ ID NO: 1, HCDR2 comprises any one of SEQ ID NOS: 2-5, HCDR3 comprises any one of SEQ ID NOS: 6-9, LCDR1 comprises SEQ ID NO: 10, LCDR2 comprises SEQ ID NO: 11, and LCDR3 comprises any one of SEQ ID NOS: 12-15. In some embodiments, the Fc region comprises any one of SEQ ID NOs: 401-413 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 401-413. In some embodiments, the heavy chain comprises any one of SEQ ID NOs: 501-513 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 501-513. In some embodiments, the light chain comprises any one of SEQ ID NO: 514 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 514. In some embodiments, the HCDR2 comprises SEQ ID NO: 2, the HCDR3 comprises SEQ ID NO: 6, and the LCDR3 comprises SEQ ID NO: 12, and wherein the Fc region comprises any one of SEQ ID NOs: 401-413 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, or 99% identical to any one of SEQ ID NOs: 401-413. In some embodiments, the antibody or antigen binding fragment comprises at least about 80% monomeric fraction as determined by size exclusion chromatography. In some embodiments, the antibody or antigen binding fragment expresses at least about 20 ug / ml total antibody, optionally about 20 ug / ml and 70 ug / mL total antibody.

[0011] Further provided are methods of treating fibrosis or an intestinal inflammatory condition, disease, or disorder in a subject in need thereof, the method comprising administering to the subject an antibody or antigen binding fragment of any antibody or antigen binding fragment disclosed herein. In some embodiments, the subject has fibrosis. In some embodiments, the subject has an intestinal inflammatory condition, disease, or disorder. In some embodiments, the intestinal inflammatory condition, disease, or disorder comprises inflammatory bowel disease (IBD). In some embodiments, the IBD comprises Crohn’s Disease. In some embodiments, the IBD comprises ulcerative colitis.

[0012] In some embodiments, antibodies or antigen binding fragments described herein comprise are present in a liquid composition a concentration of the antibody or antigen binding fragment of 10 mg / ml to 170 mg / ml. In some embodiments, the antibody or antigen binding fragment thereof is at a concentration of 10 mg / ml to 170 mg / ml. In some embodiments, the viscosity is from about 4 to about 30 mPa-s (millipascal-second (mPa s)). In some embodiments, the viscosity is from about 4 to about 10 mPa-s (millipascal-second (mPa s)).

[0013] In another aspect, provided herein, is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable framework region comprising a human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework, and a light chain variable framework region comprising a human IGKV3-20 framework or a modified human IGKV3-20 framework; wherein the heavy chain variable framework region and the light chain variable framework region collectively comprise less than about 14 amino acid modifications from the human IGHVl-46*02 framework and the human IGKV3-20 framework. In some embodiments, the heavy chain variable framework region and the light chain variable framework region collectively comprise 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, or no amino acid modifications from the human IGHV1 -46*02 framework and the human IGKV3-20 framework. In some embodiments, the amino acid modification comprises a modification at amino acid position 1 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 1 comprises A, R, N, D, C, E,G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 1comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 1 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 1 comprises E. In some embodiments, the amino acid modification comprises a modification at amino acid position 45 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 45 comprises A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 45 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 45 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 45 comprises K. In some embodiments, the amino acid modification comprises a modification at amino acid position 47 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 47 comprises R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 47 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 47 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 47 comprises R. In some embodiments, the amino acid modification comprises a modification at amino acid position 55 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 55 comprises A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 55 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 55 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 55 comprises I. In some embodiments, the amino acid modification comprises a modification at amino acid position 78 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 78 comprises A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y. In some embodiments, the amino acid at position 78 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 78 comprises an aliphatic amino acid,an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 78 comprises A. In some embodiments, the amino acid modification comprises a modification at amino acid position 80 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 80 comprises A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 80 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 80 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 80 comprises I. In some embodiments, the amino acid modification comprises a modification at amino acid position 82 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 82 comprises A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 82 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 82 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 82 comprises T. In some embodiments, the amino acid modification comprises a modification at amino acid position 89 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 89 comprises A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y. In some embodiments, the amino acid at position 89 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 89 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 89 comprises A. In some embodiments, the amino acid modification comprises a modification at amino acid position 91 in the heavy chain variable region, per Kabat numbering. In some embodiments, the amino acid at position 91 comprises A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 91 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 91 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acidat position 91 comprises L.

[0014] In some embodiments, the amino acid modifications comprise one or more of: Q1E, R45K, A47R, M55I, V78A, M80I, R82T, V89A, M91L in the heavy chain variable region, per Rabat numbering. In some embodiments, the amino acid modifications comprise Q1E. In some embodiments, the amino acid modifications comprise R45K. In some embodiments, the amino acid modifications comprise A47R. In some embodiments, the amino acid modifications comprise M55I. In some embodiments, the amino acid modifications comprise V78A. In some embodiments, the amino acid modifications comprise M80I. In some embodiments, the amino acid modifications comprise R82T. In some embodiments, the amino acid modifications comprise V89A. In some embodiments, the amino acid modifications comprise M91L.

[0015] In some embodiments, the amino acid modification comprises a modification at amino acid position 54 in the light chain variable region, per Rabat numbering. In some embodiments, the amino acid at position 54 comprises A, R, N, D, C, Q, E, G, H, I, R, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 54 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 54 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur- containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 54 comprises P. In some embodiments, the amino acid modification comprises a modification at amino acid position 55 in the light chain variable region, per Rabat numbering. In some embodiments, the amino acid at position 55 comprises A, R, N, D, C, Q, E, G, H, I, R, M, F, P, S, T, W, Y, or V. In some embodiments, the amino acid at position 55 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, the amino acid at position 55 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, the amino acid at position 55 comprises W.

[0016] In some embodiments, the amino acid modifications comprise L54P and / or L55W in the light chain variable region, per Rabat numbering. In some embodiments, the amino acid modifications comprise L54P. In some embodiments, the amino acid modifications comprise L55W.

[0017] In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR1 as set forth by SEQ ID NO: 1. In some embodiments, the antibody orantigen binding fragment comprises a heavy chain CDR2 as set forth by SEQ ID NO: 2. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR2 as set forth by SEQ ID NO: 3. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR2 as set forth by SEQ ID NO: 4. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR2 as set forth by SEQ ID NO: 5. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR3 as set forth by SEQ ID NO: 6. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR3 as set forth by SEQ ID NO: 7. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR3 as set forth by SEQ ID NO: 8. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain CDR3 as set forth by SEQ ID NO: 9. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR1 as set forth by SEQ ID NO: 10. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR2 as set forth by SEQ ID NO: 11. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR3 as set forth by SEQ ID NO: 12. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR3 as set forth by SEQ ID NO: 13. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR3 as set forth by SEQ ID NO: 14. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR3 as set forth by SEQ ID NO: 15.

[0018] In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR1 as set forth by SEQ ID NO: 304. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR2 as set forth by SEQ ID NO: 305. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR2 as set forth by SEQ ID NO: 313. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR3 as set forth by SEQ ID NO: 306. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR3 as set forth by SEQ ID NO: 307. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR3 as set forth by SEQ ID NO: 314. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR3 as set forth by SEQ ID NO: 315. In some embodiments, the antibody or antigen binding fragment comprises a heavy chain FR4 as set forth by SEQ ID NO: 308. In some embodiments, the antibody or antigen binding fragment comprises a light chain FR1 as set forth by SEQ ID NO: 309. In some embodiments, the antibody or antigen binding fragment comprises a light chain FR2 as setforth by SEQ ID NO: 310. In some embodiments, the antibody or antigen binding fragment comprises a light chain FR3 as set forth by SEQ ID NO: 311. In some embodiments, the antibody or antigen binding fragment comprises a light chain FR4 as set forth by SEQ ID NO: 312.

[0019] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising: (a) a heavy chain variable region comprising SEQ ID NO: 301(XI VQLVQ SGAEVKKPGAS VKVSCKAS [HCDR1 ] W VX2QX3PGQGLEWX4G[HCDR2] RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYCAR[HCDR3]WGQGTTVTVSS), and (b) a light chain variable region comprising SEQ ID NO: 303(EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDR F SGSGSGTDFTLTISRLEPEDF AVY Y C [LCDR3 ]FGGGTKLEIK), wherein each of XI- XI 1 is independently selected from A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V.

[0020] In some embodiments, XI comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, XI comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X2 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X2 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X3 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X3 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X4 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X4 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X5 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X5 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X6 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X6comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X7 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X7 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X8 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X8 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X9 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X9 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, XI 0 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, XI 0 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, XI 1 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, XI 1 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid.

[0021] In some embodiments, XI = Q or E, X2 = R or K, X3 = A or R, X4 = M or I, X5 = V or A, X6 = M or I, X7 = R or T, X8 = V or A, X9 = M or L, X10 = L or P, and XI 1 = L or W. In some embodiments, XI = Q. In some embodiments, XI = E. In some embodiments, X2 = R. In some embodiments, X2 = K. In some embodiments, X3 = A. In some embodiments, X3 = R. In some embodiments, X4 = M. In some embodiments, X4 = I. In some embodiments, X5 = V. In some embodiments, X5 = A. In some embodiments, X6 = M. In some embodiments, X6 = I. In some embodiments, X7 = R. In some embodiments, X7 =T. In some embodiments, X8 = V. In some embodiments, X8 = A. In some embodiments, X9 = M. In some embodiments, X9 = L. In some embodiments, XI 0 = L. In some embodiments, XI 0 = P. In some embodiments, XI 1 = L. In some embodiments, XI 1 = W.

[0022] In some embodiments, HCDR1 comprises SEQ ID NO: 1. In some embodiments, HCDR2 comprises SEQ ID NO: 2. In some embodiments, HCDR2 comprises SEQ ID NO: 3. In some embodiments, HCDR2 comprises SEQ ID NO: 4. In some embodiments, HCDR2comprises SEQ ID NO: 5. In some embodiments, HCDR3 comprises SEQ ID NO: 6. In some embodiments, HCDR3 comprises SEQ ID NO: 7. In some embodiments, HCDR3 comprises SEQ ID NO: 8. In some embodiments, HCDR3 comprises SEQ ID NO: 9. In some embodiments, LCDR1 comprises SEQ ID NO: 10. In some embodiments, LCDR2 comprises SEQ ID NO: 11. In some embodiments, LCDR3 comprises SEQ ID NO: 12. In some embodiments, LCDR3 comprises SEQ ID NO: 13. In some embodiments, LCDR3 comprises SEQ ID NO: 14. In some embodiments, the antibody or antigen binding fragment comprises a light chain CDR3 as set forth by SEQ ID NO: 15.

[0023] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising: (a) a heavy chain variable region comprising SEQ ID NO: 302(XIV QL V Q SGAEVKKPGAS VK VSCK AS [HCDR1 ] W VX2QX3PGQGLEWX4G[HCDR2] RX5 TX6TX7DTST STX8 YX9ELS SLRSEDT AVYY C [HCDR3 ] WGQGTT VT V S S), and (b) a light chain variable region comprising SEQ ID NO: 303(EIVLTQSPGTLSLSPGERATLSC[LCDR1]WYQQKPGQAPRX10X11IY[LCDR2]GIPDR F SGSGSGTDFTLTISRLEPEDF AVYY C [LCDR3 ]F GGGTKLEIK), wherein each of XI- XI 1 is independently selected from A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V.

[0024] In some embodiments, XI comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, XI comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X2 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X2 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X3 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X3 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X4 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X4 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X5 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic aminoacid. In some embodiments, X5 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X6 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X6 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X7 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X7 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X8 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X8 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, X9 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, X9 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, XI 0 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, XI 0 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid. In some embodiments, XI 1 comprises a hydrophobic amino acid, a hydrophilic amino acid, or an amphipathic amino acid. In some embodiments, XI 1 comprises an aliphatic amino acid, an aromatic amino acid, an acidic amino acid, a basic amino acid, a hydroxylic amino acid, a sulfur-containing amino acid, or an amidic amino acid.

[0025] In some embodiments, XI = Q or E, X2 = R or K, X3 = A or R, X4 = M or I, X5 = V or A, X6 = M or I, X7 = R or T, X8 = V or A, X9 = M or L, X10 = L or P, and XI 1 = L or W. In some embodiments, XI = Q. In some embodiments, XI = E. In some embodiments, X2 = R. In some embodiments, X2 = K. In some embodiments, X3 = A. In some embodiments, X3 = R. In some embodiments, X4 = M. In some embodiments, X4 = I. In some embodiments, X5 = V. In some embodiments, X5 = A. In some embodiments, X6 = M. In some embodiments, X6 = I. In some embodiments, X7 = R. In some embodiments, X7 =T. In some embodiments, X8 = V. In some embodiments, X8 = A. In some embodiments, X9 = M. In some embodiments, X9 = L. In some embodiments, XI 0 = L. In some embodiments,XI 0 = P. In some embodiments, XI 1 = L. In some embodiments, XI 1 = W.

[0026] In some embodiments, HCDR1 comprises SEQ ID NO: 1. In some embodiments, HCDR2 comprises SEQ ID NO: 2. In some embodiments, HCDR2 comprises SEQ ID NO: 3. In some embodiments, HCDR2 comprises SEQ ID NO: 4. In some embodiments, HCDR2 comprises SEQ ID NO: 5. In some embodiments, HCDR3 comprises SEQ ID NO: 6. In some embodiments, HCDR3 comprises SEQ ID NO: 7. In some embodiments, HCDR3 comprises SEQ ID NO: 8. In some embodiments, HCDR3 comprises SEQ ID NO: 9. In some embodiments, LCDR1 comprises SEQ ID NO: 10. In some embodiments, LCDR2 comprises SEQ ID NO: 11. In some embodiments, LCDR3 comprises SEQ ID NO: 12. In some embodiments, LCDR3 comprises SEQ ID NO: 13. In some embodiments, LCDR3 comprises SEQ ID NO: 14. In some embodiments, LCDR3 comprises SEQ ID NO: 15.

[0027] In some embodiments, the heavy chain variable region comprises SEQ ID NO: 101. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 102. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 103. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 104. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 105. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 106. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 107. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 108. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 109. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 110. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 111. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 112. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 113. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 114. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 115. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 116. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 117. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 118. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 119. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 120. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 121. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 122. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 123. In someembodiments, the heavy chain variable region comprises SEQ ID NO: 124. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 125. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 126. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 127. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 128. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 129. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 130. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 131. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 132. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 133. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 134. In some embodiments, the heavy chain variable region comprises SEQ ID NO: 135. In some embodiments, the light chain variable region comprises SEQ ID NO: 201. In some embodiments, the light chain variable region comprises SEQ ID NO: 202. In some embodiments, the light chain variable region comprises SEQ ID NO: 203. In some embodiments, the light chain variable region comprises SEQ ID NO: 204. In some embodiments, the light chain variable region comprises SEQ ID NO: 205. In some embodiments, the light chain variable region comprises SEQ ID NO: 206.

[0028] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising an amino acid sequence at least about 96% identical to SEQ ID NO: 104, and a light chain variable domain comprising an amino acid sequence at least about 97% identical to SEQ ID NO: 201. In some embodiments, the heavy chain variable domain comprises an amino acid sequence at least about 97% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises an amino acid sequence at least about 98% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises an amino acid sequence at least about 99% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises SEQ ID NO: 104. In some embodiments, the light chain variable domain comprises an amino acid sequence at least about 98% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises an amino acid sequence at least about 99% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises SEQ ID NO: 201.

[0029] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variabledomain comprising an amino acid sequence at least about 99% identical to SEQ ID NO: 107, and a light chain variable domain comprising an amino acid sequence at least about 97% identical to SEQ ID NO: 201. In some embodiments, the heavy chain variable domain comprises SEQ ID NO: 107. In some embodiments, the light chain variable domain comprises an amino acid sequence at least about 98% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises an amino acid sequence at least about 99% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises SEQ ID NO: 201.

[0030] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 101-135, and a light chain variable domain comprising an amino acid sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 201-206. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%,99%, or 100% identical to SEQ ID NO: 105. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107.In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111.In some embodiments, the heavy chain variable domain comprises a sequence at least about95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 113. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 115.In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 118. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119.In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 120. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 123.In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 124. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 125. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 126. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127.In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 129. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 130. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 131.In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 132. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 133. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134. In some embodiments, the heavy chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135.In some embodiments, the light chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. In some embodiments, the light chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. In some embodiments, the light chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203. In some embodiments, the light chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.In some embodiments, the light chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. In some embodiments, the light chain variable domain comprises a sequence at least about 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 206.

[0031] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 101, and a light chain variable domain comprising SEQ ID NOS: 201.

[0032] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 102, and a light chain variable domain comprising SEQ ID NOS: 201.

[0033] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 103, and a light chain variable domain comprising SEQ ID NOS: 202.

[0034] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 104, and a light chain variable domain comprising SEQ ID NOS: 201.

[0035] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 105, and a light chain variable domain comprising SEQ ID NOS: 201.

[0036] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 103, and a light chain variable domain comprising SEQ ID NOS: 201.

[0037] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 106, and a light chain variable domain comprising SEQ ID NOS: 201.

[0038] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 107, and a light chain variable domain comprising SEQ ID NOS: 201.

[0039] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 108, and a light chain variable domain comprising SEQ ID NOS: 202.

[0040] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 109, and a light chain variable domain comprising SEQ ID NOS: 202.

[0041] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 108, and a light chain variable domain comprising SEQ ID NOS: 201.

[0042] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 109, and a light chain variable domain comprising SEQ ID NOS: 201.

[0043] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variabledomain comprising SEQ ID NO: 108, and a light chain variable domain comprising SEQ ID NOS: 203.

[0044] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 108, and a light chain variable domain comprising SEQ ID NOS: 204.

[0045] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 107, and a light chain variable domain comprising SEQ ID NOS: 204.

[0046] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 107, and a light chain variable domain comprising SEQ ID NOS: 202.

[0047] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 110, and a light chain variable domain comprising SEQ ID NOS: 204.

[0048] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 111, and a light chain variable domain comprising SEQ ID NOS: 201.

[0049] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 112, and a light chain variable domain comprising SEQ ID NOS: 201.

[0050] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 113, and a light chain variable domain comprising SEQ ID NOS: 204.

[0051] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 114, and a light chain variable domain comprising SEQ ID NOS: 201.

[0052] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 115, and a light chain variable domain comprising SEQ ID NOS: 202.

[0053] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 116, and a light chain variable domain comprising SEQ ID NOS: 201.

[0054] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 117, and a light chain variable domain comprising SEQ ID NOS: 201.

[0055] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 118, and a light chain variable domain comprising SEQ ID NOS: 204.

[0056] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 114, and a light chain variable domain comprising SEQ ID NOS: 204.

[0057] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 102, and a light chain variable domain comprising SEQ ID NOS: 204.

[0058] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 104, and a light chain variable domain comprising SEQ ID NOS: 204.

[0059] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 119, and a light chain variable domain comprising SEQ ID NOS: 204.

[0060] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variabledomain comprising SEQ ID NO: 119, and a light chain variable domain comprising SEQ ID NOS: 201.

[0061] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 101, and a light chain variable domain comprising SEQ ID NOS: 204.

[0062] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 105, and a light chain variable domain comprising SEQ ID NOS: 204.

[0063] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 120, and a light chain variable domain comprising SEQ ID NOS: 204.

[0064] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 121, and a light chain variable domain comprising SEQ ID NOS: 202.

[0065] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 122, and a light chain variable domain comprising SEQ ID NOS: 202.

[0066] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 122, and a light chain variable domain comprising SEQ ID NOS: 204.

[0067] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 123, and a light chain variable domain comprising SEQ ID NOS: 202.

[0068] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 124, and a light chain variable domain comprising SEQ ID NOS: 202.

[0069] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 125, and a light chain variable domain comprising SEQ ID NOS: 205.

[0070] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 116, and a light chain variable domain comprising SEQ ID NOS: 205.

[0071] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1A (TL1A), comprising a heavy chain variable domain comprising SEQ ID NO: 117, and a light chain variable domain comprising SEQ ID NOS: 205.

[0072] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 126, and a light chain variable domain comprising SEQ ID NOS: 205.

[0073] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 127, and a light chain variable domain comprising SEQ ID NOS: 205.

[0074] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 127, and a light chain variable domain comprising SEQ ID NOS: 201.

[0075] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 121, and a light chain variable domain comprising SEQ ID NOS: 201.

[0076] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 122, and a light chain variable domain comprising SEQ ID NOS: 205.

[0077] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variabledomain comprising SEQ ID NO: 122, and a light chain variable domain comprising SEQ ID NOS: 201.

[0078] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 122, and a light chain variable domain comprising SEQ ID NOS: 206.

[0079] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 124, and a light chain variable domain comprising SEQ ID NOS: 205.

[0080] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 124, and a light chain variable domain comprising SEQ ID NOS: 201.

[0081] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 128, and a light chain variable domain comprising SEQ ID NOS: 205.

[0082] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 128, and a light chain variable domain comprising SEQ ID NOS: 206.

[0083] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 129, and a light chain variable domain comprising SEQ ID NOS: 205.

[0084] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 130, and a light chain variable domain comprising SEQ ID NOS: 205.

[0085] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 131, and a light chain variable domain comprising SEQ ID NOS: 205.

[0086] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 132, and a light chain variable domain comprising SEQ ID NOS: 205.

[0087] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 133, and a light chain variable domain comprising SEQ ID NOS: 205.

[0088] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 134, and a light chain variable domain comprising SEQ ID NOS: 205.

[0089] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 135, and a light chain variable domain comprising SEQ ID NOS: 205.

[0090] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 132, and a light chain variable domain comprising SEQ ID NOS: 201.

[0091] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 126, and a light chain variable domain comprising SEQ ID NOS: 201.

[0092] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain variable domain comprising SEQ ID NO: 130, and a light chain variable domain comprising SEQ ID NOS: 201.

[0093] Further provided herein is an antibody or antigen binding fragment thereof that binds to tumor necrosis factor-like protein 1 A (TL1 A), comprising a heavy chain domain comprising any one of SEQ ID NOs: 501-513, and a light chain domain comprising SEQ ID NOS: 514.

[0094] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable region comprising: (a) anHCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 1; (b) an HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 2-5; and (c) an HCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 6-9; and the light chain variable region comprises: (d) an LCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 10; (e) an LCDR2 comprising an amino acid sequence set forth by SEQ ID NO: 11; (f) an LCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 12-15; and a fragment crystallizable (Fc) region comprising reduced antibody- dependent cell-mediated cytotoxicity (ADCC) function as compared to human IgGl and / or reduced complement-dependent cytotoxicity (CDC) as compared to human IgGl . In some embodiments, the human IgGl comprises SEQ ID NO: 320. In some embodiments, the ADCC function of the Fc region comprising reduced ADCC is at least about 50% reduced as compared to human IgGl. In some embodiments, the CDC function of the Fc region comprising reduced ADCC is at least about 50% reduced as compared to human IgGl. In some embodiments, the Fc region comprises a human IgGl comprising (a) 297A, 297Q, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235 S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329 A, 329G, 329Y, (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H,2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w)270 A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293 S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440 A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu)L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. In some embodiments, the antibody of antigen binding fragment comprises a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P and L235E, or (b) S228P, F234A, and L235A, per Rabat numbering. In some embodiments,the antibody of antigen binding fragment comprises a human IgG2 Fc region; IgG2-IgG4 cross-subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2o). In some embodiments, the antibody of antigen binding fragment comprises a human Fc region comprising high mannose glycosylation. In some embodiments, the Fc region comprises a human IgGl with a substitution selected from 297A, 297Q, 297D, 279F, 279K, 279L, 228P, 235A, 235E, 235G, 235Q, 235R, 235S, 237A, 237E, 237K, 237N, 237R, 268K, 269N, 269Q, 270 A, 270G, 270M, 270N, 424H, 424M, and 424V, per Rabat numbering. In some embodiments, the Fc region comprises a human IgGl with a substitution selected from 271T, 272N, 292E, 292F, 292G, 2921, 293S, 301W, 304E, 311E,311G, 31 IS, 255N, 256H, 256K, 256R, 256V, 316F, 328V, 330R, 339E, 339L, 3431, 343V, 373 A, 373G, 373S, 376E, 376W, 376Y, 380D, 382D, 382P, 385P, 234A, 234V, 234F, 233P, 328A, 327Q and 327T, per Rabat numbering. In some embodiments, the Fc region comprises a human IgGl with a substitution selected from 329A, 329G, 329Y, 33 IS, 236F, 236R,238 A, 238E, 238G, 238H, 2381, 238V, 238W, 238 Y, 248 A, 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, 254V, 264S, 265H, 265R, 265 S, 265 Y, 265 A, 267G, 267H, 2671, 267R, 4341, 438G, 439E, 439H, 439Q, 440A, 440D, 440E, 440F, 440M, 440T, and 440V, per Rabat numbering. In some embodiments, the antibody or antigen binding fragment comprises a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362. In some embodiments, HCDR1 comprises SEQ ID NO: 1. In some embodiments, HCDR2 comprises SEQ ID NO: 2. In some embodiments, HCDR2 comprises SEQ ID NO: 3. In some embodiments, HCDR2 comprises SEQ ID NO: 4. In some embodiments, HCDR2 comprises SEQ ID NO: 5. In some embodiments, HCDR3 comprises SEQ ID NO: 6. In some embodiments, HCDR3 comprises SEQ ID NO: 7. In some embodiments, HCDR3 comprises SEQ ID NO: 8. In some embodiments, HCDR3 comprises SEQ ID NO: 9. In some embodiments, LCDR1 comprises SEQ ID NO: 10. In some embodiments, LCDR2 comprises SEQ ID NO: 11. In some embodiments, LCDR3 comprises SEQ ID NO: 12. In some embodiments, LCDR3 comprises SEQ ID NO: 13. In some embodiments, LCDR3 comprises SEQ ID NO: 14. In some embodiments, LCDR3 comprises SEQ ID NO: 15.

[0095] In another aspect, provided herein is an antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable region comprising: (a) an HCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 1; (b) an HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 2-5; and (c) anHCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 6-9; and the light chain variable region comprises: (d) an LCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 10; (e) an LCDR2 comprising an amino acid sequence set forth by SEQ ID NO: 11; and (f) an LCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 12-15. In some embodiments, the heavy chain variable region comprises human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework. In some embodiments, the light chain variable framework region comprising a human IGKV3-20 framework or a modified human IGKV3-20 framework. In some embodiments, the heavy chain variable region comprises one of more of the following amino acids: IE, 45K, 47R,551, 78A, 801, 82T, 89A, 91L, per Rabat numbering. In some embodiments, the heavy chain variable region comprises IE. In some embodiments, the heavy chain variable region comprises 45K. In some embodiments, the heavy chain variable region comprises 47R. In some embodiments, the heavy chain variable region comprises 551. In some embodiments, the heavy chain variable region comprises 78A. In some embodiments, the heavy chain variable region comprises 801. In some embodiments, the heavy chain variable region comprises 82T. In some embodiments, the heavy chain variable region comprises 89A. In some embodiments, the heavy chain variable region comprises 91L. In some embodiments, the light chain variable region comprises one or more of the following amino acids: 54P and 55W, per Rabat numbering. In some embodiments, the light chain variable region comprises 54P. In some embodiments, the light chain variable region comprises 55W. In some embodiments, the HCDR2 comprises SEQ ID NO: 2. In some embodiments, the HCDR2 comprises SEQ ID NO: 3. In some embodiments, the HCDR2 comprises SEQ ID NO: 4. In some embodiments, the HCDR2 comprises SEQ ID NO: 5. In some embodiments, the HCDR3 comprises SEQ ID NO: 6. In some embodiments, the HCDR3 comprises SEQ ID NO: 7. In some embodiments, the HCDR3 comprises SEQ ID NO: 8. In some embodiments, the HCDR3 comprises SEQ ID NO: 9. In some embodiments, the LCDR3 comprises SEQ ID NO: 12. In some embodiments, the LCDR3 comprises SEQ ID NO: 13. In some embodiments, the LCDR3 comprises SEQ ID NO: 14. In some embodiments, LCDR3 comprises SEQ ID NO: 15.

[0096] In some embodiments, an antibody or antigen binding fragment described herein comprises a human IgGl Fc region comprising (a) 297A, 297Q, or 297D, (b) 279F, 279R, or 279L, (c) 228P, (d) 235A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237R, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V, 238W, or238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270 A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd)311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss)440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. In some embodiments, an antibody of antigen binding fragment herein comprises a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P and L235E, or (b) S228P, F234A, and L235A, per Rabat numbering. In some embodiments, an antibody of antigen binding fragment herein comprises a human IgG2 Fc region; IgG2-IgG4 cross subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2o). In some embodiments, an antibody of antigen binding fragment herein comprises a human Fc region comprising high mannose glycosylation. In some embodiments, any of the antibody or antigen binding fragments described herein comprise a human IgG4 Fc region.

[0097] In some embodiments, an antibody or antigen binding fragment described herein comprises a human IgGl with a substitution selected from 297A, 297Q, 297D, 279F, 279R, 279L, 228P, 235A, 235E, 235G, 235Q, 235R, 235S, 237A, 237E, 237R, 237N, 237R, 268R, 269N, 269Q, 270A, 270G, 270M, 270N, 424H, 424M, and 424V, per Rabat numbering. In some embodiments, an antibody or antigen binding fragment described herein comprises a human IgGl with a substitution selected from 27 IT, 272N, 292E, 292F, 292G, 2921, 293 S, 301W, 304E, 311E, 311G, 31 IS, 255N, 256H, 256R, 256R, 256V, 316F, 328V, 330R, 339E, 339L, 3431, 343V, 373 A, 373G, 373S, 376E, 376W, 376Y, 380D, 382D, 382P, 385P, 234A, 234V, 234F, 233P, 328A, 327Q and 327T, per Rabat numbering. In some embodiments, an antibody or antigen binding fragment described herein comprises a human IgGl with asubstitution selected from 329A, 329G, 329Y, 33 IS, 236F, 236R, 238A, 238E, 238G, 238H, 2381, 238V, 238W, 238 Y, 248 A, 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, 254V, 264S, 265H, 265K, 265S, 265Y, 265A, 267G, 267H, 2671, 267K, 4341, 438G, 439E,439H, 439Q, 440 A, 440D, 440E, 440F, 440M, 440T, and 440V, per Kabat numbering.

[0098] In some embodiments, an antibody or antigen binding fragment described herein comprises a Fc region comprising a sequence at least about 90%, 91%, 92%, 93%, 94%,95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362.

[0099] In some embodiments, an antibody or antigen binding fragment described herein comprises at least about 80% monomeric fraction as determined by size exclusion chromatography. In some embodiments, an antibody or antigen binding fragment described herein comprises at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% monomeric fraction. In some embodiments, the size exclusion chromatography comprises injecting purified antibody or antigen binding fragment onto a size exclusion column, wherein the antibody or antigen binding fragment is purified by protein A. In some embodiments, the antibody or antigen binding fragment is purified as described in Example 2. In some embodiments, the antibody or antigen binding fragment is expressed under conditions described in Example 2. In some embodiments, the size exclusion chromatography column has an inner diameter of 4.6 mm. In some embodiments, the size exclusion chromatography column has a length of 150 mm. In some embodiments, the size exclusion chromatography column has a pore size of 200 A. In some embodiments, the size exclusion chromatography column has a particle size of 1.7 micrometer. In some embodiments, the size exclusion chromatography column is ACQUITY UPLC BEH200 SEC column. In some embodiments, the antibody or antigen binding fragment is injected at a total volume of 15 pL. In some embodiments, the antibody or antigen binding fragment is injected at a concentration of about 0.1 pg / pL to about 1.0 pg / pL. In some embodiments, the size exclusion chromatography is performed on a Shimadzu UPLC instrument. In some embodiments, the size exclusion chromatography is performed at a flow rate of 0.2 mL / min. In some embodiments, the size exclusion chromatography is performed at a column oven temperature of 30°C. In some embodiments, the percentage of monomer is calculated using Shimadzu software. In some embodiments, the size exclusion chromatography is performed as described in Example 2.

[0100] In some embodiments, an antibody or antigen binding fragment described herein expresses at least about 20 ug / ml total antibody. In some embodiments, an antibody or antigen binding fragment described herein expresses between about 20 ug / ml and 70 ug / mLtotal antibody. In some embodiments, the antibody or antigen binding fragment is expressed in FreeStyle 293-F cells. In some embodiments, the antibody or antigen binding fragment is expressed as described in Example 2. In some embodiments, the antibody or antigen binding fragment expression level is quantified using Enzyme-Linked Immunosorbent assay (ELISA). In some embodiments, the ELISA comprises coating a surface of a substrate with a capture antibody that binds to a human or humanized antibody, applying the antibody or antigen binding fragment to the substrate, and applying to the substrate a second antibody that binds to a human or humanized antibody. In some embodiments, the capture antibody comprises an anti-kappa antibody. In some embodiments, the second antibody comprises an anti-Fc antibody. In some embodiments, the ELISA is performed as described in Example 2.

[0101] Further provided herein are methods of treating inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject an antibody or antigen binding fragment described herein. In some embodiments, the IBD comprises Crohn’s Disease. In some embodiments, the IBD comprises ulcerative colitis.BRIEF DESCRIPTION OF THE FIGURES

[0102] Exemplary embodiments are illustrated in referenced figures. It is intended that the embodiments and figures disclosed herein are to be considered illustrative rather than restrictive.

[0103] FIGS. 1A-1C show chromatograms for analytical size exclusion chromatography of anti-TLl A antibodies.

[0104] FIG. 2 depicts inhibition of interferon gamma in human blood with anti-TLl A antibodies.

[0105] FIGS. 3A-3C depict a PLS model demonstrating effect of pH and protein concentration on viscosity. FIG. 3A shows a PLS graph, FIG. 3B shows a model of the predicted viscosity versus anti-TLl A antibody concentration in mg / mL, and FIG. 3C shows a model of the estimated viscosity versus actual viscosity. Viscosity units are in mPa-s.DESCRIPTION OF THE INVENTION

[0106] Tumor necrosis factor-like protein 1 A (TL1 A) is a proinflammatory molecule which stimulates proliferation and effector functions of CD8 (+) cytotoxic T cells as well as Thl, Th2, and Thl7 cells in the presence of TCR stimulation. TL1A has been associated with the development and severity of inflammatory bowel disease (IBD), such as Crohn’s Disease (CD) and ulcerative colitis. TL1A is believed to be involved in the pathogenesis of IBD by bridging the innate and adaptive immune response, modulating adaptive immunity byaugmenting Thl, Th2, and Thl7 effector cell function, and T-cell accumulation and immunopathology of inflamed tissue. TL1 A is a target associated with both intestinal inflammation and intestinal fibrosis, which was clinically validated in a Phase 2a clinical trial in UC. In addition, preclinical and human genetic association data suggests that TL1 A is a potential therapeutic target in CD. The present disclosure describes optimized antibodies against TL1 A and offers novel therapeutics for the treatment of IBD. The anti-TLIA antibodies described herein may substantially improve outcomes for moderate-to-severe IBD patients who are predisposed to increased TL1 A expression. As an example, the patients are selected for treatment with an anti-TLIA antibody herein based on increased expression of TL1 A in the patient as compared to a reference level (e.g., from a subject who does not have IBD). The patients may be selected for increased TL1 A expression as determined by a genotyping assay to determine the presence of a genotype associated with increased TL1 A expression. TL1A and nucleic acids encoding TL1A (Tumor Necrosis Factor Ligand Superfamily Member 15 ( TNFSF15 )) are provided as set forth by Entrez Gene: 9966; UniProtKB: 095150. Accordingly, the present disclosure further provides methods of treating subjects having a increased TL1 A expression with an antibody described herein.Antibodies

[0107] In one aspect, provided herein are antibodies and antigen-binding fragments. In some embodiments, an antibody comprises an antigen-binding fragment that refers to a portion of an antibody having antigenic determining variable regions of an antibody. Examples of antigen-binding fragments include, but are not limited to Fab, Fab’, F(ab’)2, and Fv fragments, linear antibodies, single chain antibodies, and multispecific antibodies formed from antibody fragments. In some embodiments, an antibody refers to an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule. In some embodiments, an antibody includes intact polyclonal antibodies, intact monoclonal antibodies, antibody fragments (such as Fab, Fab’, F(ab’)2, and Fv fragments), single chain Fv (scFv) mutants, a CDR-grafted antibody, multispecific antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antigen determination portion of an antibody, and any other modified immunoglobulin molecule comprising an antigen recognition site so long as the antibodies exhibit the desired biological activity. An antibody can be of any the five major classes of immunoglobulins: IgA, IgD,IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g. IgGl, IgG2, IgG3, IgG4, IgAl and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and well-known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated to other molecules such as toxins, radioisotopes, etc.

[0108] In some embodiments, a humanized antibody refers to forms of non-human (e.g., murine) antibodies having specific immunoglobulin chains, chimeric immunoglobulins, or fragments thereof that contain minimal non-human (e.g., murine) sequences. In a non limiting example, a humanized antibody comprises less than about 40% non-human sequence in the variable region. In some cases, a humanized antibody comprises less than about 20% non-human sequence in a full-length antibody sequence. In a further non-limiting example, a humanized antibody comprises less than about 20% non-human sequence in the framework region of each of the heavy chain and light chain variable regions. For instance, the humanized antibody comprises less than about 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% non-human sequence in the framework region of each of the heavy chain and light chain variable regions. As another example, the humanized antibody comprises about or less than about 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 non-human sequences in the framework region of each of the heavy chain and light chain variable regions. In some cases, humanized antibodies are human immunoglobulins in which residues from the complementarity determining region (CDR) are replaced by residues from the CDR of a non-human species (e.g., mouse, rat, rabbit, hamster) that have the desired specificity, affinity, and capability. These humanized antibodies may contain one or more non-human species mutations, e.g., the heavy chain comprises about 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 non-human species mutations in the framework region, and the light chain comprises about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 non-human species mutations in the framework region. The humanized heavy chain variable domain may comprise IGHV1 -46*02 framework with no or fewer than about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations. The humanized light chain variable domain may comprise IGKV3-20 framework with no or fewer than about 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 amino acid mutations.

[0109] In some embodiments, chimeric antibodies refer to antibodies wherein the sequence of the immunoglobulin molecule is derived from two or more species. As a non limiting example, the variable region of both light and heavy chains corresponds to the variable region of antibodies derived from one species of mammals (e.g., mouse, rat, rabbit,etc.) with the desired specificity, affinity, and capability while the constant regions are homologous to the sequences in antibodies derived from another (usually human) to avoid eliciting an immune response in that species.

[0110] The terms “complementarity determining region,” and “CDR,” which are synonymous with “hypervariable region” or “HVR,” are known in the art to refer to non contiguous sequences of amino acids within antibody variable regions, which confer antigen specificity and / or binding affinity. In general, there are three CDRs in each heavy chain variable region (CDR-H1, CDR-H2, CDR-H3) and three CDRs in each light chain variable region (CDR-L1, CDR-L2, CDR-L3). “Framework regions” and “FR” are known in the art to refer to the non-CDR portions of the variable regions of the heavy and light chains. In general, there are four FRs in each full-length heavy chain variable region (FR-H1, FR-H2, FR-H3, and FR-H4), and four FRs in each full-length light chain variable region (FR-L1, FR- L2, FR-L3, and FR-L4). The precise amino acid sequence boundaries of a given CDR or FR can be readily determined using any of a number of well-known schemes, including those described by Rabat et al. (1991), “Sequences of Proteins of Immunological Interest,” 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (“Rabat” numbering scheme), Al-Lazikani et al., {\991)JMB 273,927-948 (“Chothia” numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), “Antibody-antigen interactions: Contact analysis and binding site topography,” J. Mol. Biol. 262, 732-745.” (“Contact” numbering scheme); Lefranc MP et al.,“IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Dev Comp Immunol , 2003 Jan;27(l):55-77 (“IMGT” numbering scheme); Honegger A and Pliickthun A, “Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool,” J Mol Biol, 2001 Jun 8;309(3):657-70, (“Aho” numbering scheme); and Whitelegg NR and Rees AR, “WAM: an improved algorithm for modelling antibodies on the WEB,” Protein Eng. 2000 Dec;13(12):819-24 (“AbM” numbering scheme. In certain embodiments, the CDRs of the antibodies described herein can be defined by a method selected from Rabat, Chothia, IMGT, Aho, AbM, or combinations thereof.

[0111] In some embodiments, an antibody that specifically binds to a protein indicates that the antibody reacts or associates more frequently, more rapidly, with greater duration, with greater affinity, or with some combination of the above to the protein than with alternative substances, including unrelated proteins.

[0112] In some embodiments, the terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer maybe linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as fusion with another polypeptide and / or conjugation, e.g., with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (for example, unnatural amino acids, etc.), as well as other modifications known in the art.

[0113] In some embodiments, a protein such as an antibody described herein comprises a hydrophobic amino acid. Non-limiting exemplary hydrophobic amino acids include glycine (Gly), proline (Pro), phenylalanine (Phe), alanine (Ala), isoleucine (lie), leucine (Leu), and valine (Val). In some embodiments, a protein such as an antibody described herein comprises a hydrophilic amino acid. Non-limiting exemplary hydrophilic amino acids include serine (Ser), threonine (Thr), aspartic acid (Asp), glutamic acid (Glu), cysteine (Cys), asparagine (Asn), glutamine (Gin), arginine (Arg), and histidine (His). In some embodiments, a protein such as an antibody described herein comprises an amphipathic amino acid. Non-limiting exemplary amphipathic amino acids include lysine (Lys), tryptophan (Trp), tyrosine (Tyr), and methionine (Met). In some embodiments, a protein such as an antibody described herein comprises an aliphatic amino acid. Non-limiting exemplary aliphatic amino acids include alanine (Ala), isoleucine (lie), leucine (Leu) and valine (Val). In some embodiments, a protein such as an antibody described herein comprises an aromatic amino acid. Non-limiting exemplary aromatic amino acids include phenylalanine (Phe), tryptophan (Trp), and tyrosine (Tyr). In some embodiments, a protein such as an antibody described herein comprises an acidic amino acid. Non-limiting exemplary acidic amino acids include aspartic acid (Asp) and glutamic acid (Glu). In some embodiments, a protein such as an antibody described herein comprises a basic amino acid. Non-limiting exemplary basic amino acids include arginine (Arg), histidine (His), and lysine (Lys). In some embodiments, a protein such as an antibody described herein comprises a hydroxylic amino acid. Non-limiting exemplary hydroxylic amino acids include serine (Ser) and threonine (Thr). In some embodiments, a protein such as an antibody described herein comprises a sulfur-containing amino acid. Non limiting exemplary sulfur-containing amino acids include cysteine (Cys) and methionine (Met). In some embodiments, a protein such as an antibody described herein comprises an amidic amino acid. Non-limiting exemplary amidic amino acids include asparagine (Asn) and glutamine (Gin).

[0114] In some embodiments, “polynucleotide,” or “nucleic acid,” as used interchangeably herein, refer to polymers of nucleotides of any length, and include DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogs, or any substrate that can be incorporated into a polymer by DNA or RNA polymerase. A polynucleotide may comprise modified nucleotides, such as, but not limited to methylated nucleotides and their analogs or non-nucleotide components. Modifications to the nucleotide structure may be imparted before or after assembly of the polymer. A polynucleotide may be further modified after polymerization, such as by conjugation with a labeling component.

[0115] Percent (%) sequence identity with respect to a reference polypeptide sequence is the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are known for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Appropriate parameters for aligning sequences are able to be determined, including algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, Calif., or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

[0116] In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows: 100 times the fraction X / Y, where X is the number of amino acid residues scored as identical matches by the sequencealignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

[0117] In some embodiments, the term “about” means within 10% of the stated amount. For instance, an antibody variable region comprising about 80% identity to a reference variable region may comprise 72% to 88% identity to the reference variable region.

[0118] In certain aspects, antibodies are described herein that specifically bind to TL1 A (Entrez Gene: 9966; UniProtKB: 095150). In some embodiments, the antibodies specifically bind to soluble TL1 A. In some embodiments, the antibodies specifically bind to membrane bound TL1A. In some embodiments, an anti-TLl A antibody is provided having a heavy chain comprising four heavy chain framework regions (HCFR) and three heavy chain complementarity-determining regions (HCDR): HCFR1, HCDR1, HCFR2, HCDR2, HCFR3, HCDR3, and HCFR4; and a light chain comprising four light chain framework regions (LCFR) and three light chain complementarity-determining regions (LCDR): LCFR1, LCDR1, LCFR2, LCDR2, LCFR3, LCDR3, and LCFR4. An anti-TLIA antibody may comprise any region provided herein, for example, as provided in Tables 6-11, the examples, and the sequences.Exemplary anti-TLIA CDRs

[0119] In certain embodiments, an anti-TLIA antibody comprises a HCDR1 as set forth by SEQ ID NO: 1. In certain embodiments, an anti-TLIA antibody comprises a HCDR2 as set forth by any one of SEQ ID NOS: 2-5. In certain embodiments, an anti-TLIA antibody comprises a HCDR3 as set forth by any one of SEQ ID NOS: 6-9. In certain embodiments, an anti-TLIA antibody comprises a LCDR1 as set forth by SEQ ID NO: 10. In certain embodiments, an anti-TLIA antibody comprises a LCDR2 as set forth by SEQ ID NO: 11. In certain embodiments, an anti-TLIA antibody comprises a LCDR3 as set forth by any one of SEQ ID NOS: 12-15.

[0120] In certain embodiments, an anti-TLIA antibody comprises a HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 selected from Table 6. In certain embodiments, an anti- TLIA antibody comprises the CDRs set forth in antibody A as shown in Table 10. In certainembodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody B as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody C as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody D as shown in Table 10. In certain embodiments, an anti- TLl A antibody comprises the CDRs set forth in antibody E as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody F as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody G as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody H as shown in Table 10. In certain embodiments, an anti- TLl A antibody comprises the CDRs set forth in antibody A2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody B2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody C2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody D2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody E2 as shown in Table 10.In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody F2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody G2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody H2 as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody I as shown in Table 10. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody 12 as shown in Table 10.

[0121] In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in any one of the antibodies in Table 1. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A217, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A220, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A223, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A219, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A221, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A200,wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A213, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A212, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A107, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A205, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A211, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A199, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A15, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A30, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A 100, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A181, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A129, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A214, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A216, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A122, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A222, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A188, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A203, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certainembodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A147, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A127, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A126, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A160, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A157, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A159, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A218, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A158, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A125, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A103, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A64, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A67, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A138, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A68, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A94, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A110, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A197, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A112,wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A169, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A173, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A179, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A148, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A115, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A149, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A134, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A113, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A151, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A96, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A132, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A196, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A172, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A75, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A174, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A109, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the CDRs set forth in antibody A198, wherein the CDRs are defined by the Kabat, Chothia, or IMGT method. In certainembodiments, an anti-TLl A antibody comprises the CDRs set forth in antibody A170, wherein the CDRs are defined by the Rabat, Chothia, or IMGT method.

[0122] Exemplary anti-TLIA Framework Regions

[0123] Tables 7-9A and Table 11 provides exemplary framework and variable region sequences.

[0124] In some embodiments, an anti-TLIA antibody comprises a heavy chain framework comprising SEQ ID NO: 301(XI VQLVQ SGAEVKKPGAS VKVSCKAS [HCDR1 ] W VX2QX3PGQGLEWX4G[HCDR2] RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYCAR[HCDR3]WGQGTTVTVSS). In some cases, XI is Q. In some cases, XI = E. In some cases, X2 = R. In some cases, X2 = K. In some cases, X3 = A. In some cases, X3 = R. In some cases, X4 = M. In some cases, X4 =I. In some cases, X5 = V. In some cases, X5 = A. In some cases, X6 = M. In some cases, X6 = I. In some cases, X7 = R. In some cases, X7 = T. In some cases, X8 = V. In some cases, X8 = A. In some cases, X9 = M. In some cases, X9 = L. In some embodiments, XI is at position 1 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X2 is at position 45 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X3 is at position 47 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X4 is at position 55 of IGHVl-46*02 as determined by Rabat numbering. In some embodiments, X5 is at position 78 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X6 is at position 80 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X7 is at position 82 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X8 is at position 89 of IGHV1 -46*02 as determined by Rabat numbering. In some embodiments, X9 is at position 91 of IGHV1- 46*02 as determined by Rabat numbering.

[0125] In one aspect, provided herein is a first embodiment of an anti-TLIA antibody comprising a heavy chain framework comprising IGHV1 -46*02, or a variant thereof, wherein the variant comprises between about 1 and about 9 amino acid substitutions, or between about 1 and about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from IGHVl-46*02 framework. Additional embodiments include: (2) The anti-TLIA of embodiment (1), wherein the heavy chain framework comprises SEQ ID NO: 301. (3) The anti-TLIA of embodiment 2, wherein XI = Q. (4) The anti-TLIA of embodiment 2, wherein XI = E. (5) The anti-TLIA of any one of embodiments 2-4, wherein X2 = R. (6) The anti-TLIA of any one of embodiments 2-4, wherein X2 = R. (7) The anti-TLIA of any one of embodiments 2-6, wherein X3 = A. (8)The anti-TLl A of any one of embodiments 2-6, wherein X3 = R. (9) The anti-TLl A of any one of embodiments 2-8, wherein X4 = M. (10) The anti-TLIA of any one of embodiments 2-8, wherein X4 = 1. (11) The anti-TLIA of any one of embodiments 2-10, wherein X5 = V. (12) The anti-TLIA of any one of embodiments 2-10, wherein X5 = A. (13) The anti-TLIA of any one of embodiments 2-12, wherein X6 = M. (14) The anti-TLIA of any one of embodiments 2-12, wherein X6 = I. (15) The anti-TLIA of any one of embodiments 2-14, wherein X7 = R. (16) The anti-TLIA of any one of embodiments 2-14, wherein X7 = T. (17) The anti-TLIA of any one of embodiments 2-16, wherein X8 = V. (18) The anti-TLIA of any one of embodiments 2-16, wherein X8 = A. (19) The anti-TLIA of any one of embodiments 2-18, wherein X9 = M. (20) The anti-TLIA of any one of embodiments 2-4, wherein X9 = L. (21) The anti-TLIA of any one of embodiments 1-20, comprising antibody A. (22) The anti- TLIA of any one of embodiments 1-20, comprising antibody B. (23) The anti-TLIA of any one of embodiments 1-20, comprising antibody C. (24) The anti-TLIA of any one of embodiments 1-20, comprising antibody D. (25) The anti-TLIA of any one of embodiments 1-20, comprising antibody E. (26) The anti-TLIA of any one of embodiments 1-20, comprising antibody F. (27) The anti-TLIA of any one of embodiments 1-20, comprising antibody G or I. (28) The anti-TLIA of any one of embodiments 1-20, comprising antibody H. (29) The anti-TLIA of any one of embodiments 1-28, comprising a human IgGl Fc region comprising: (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A,235E, 235 G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238 A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293 S, (bb) 301W, (cc) 304E, (dd) 31 IE, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343 V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A,(ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii)D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Kabat numbering. As used herein, any combination of a group, such as (a) to (uu), includes at least about two or more items from the group, e.g., any combination of a group of (a) to (uu) includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 3637, 38, 39, 40, 41, 42, 43, 44, 45, 46, and up to 47 or all of the members of the group. (30) The anti-TLIA of any one of embodiments 1-28, comprising a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P, (b) S228P and L235E, or (c) S228P, F234A, and L235A, per Kabat numbering. (31) The anti-TLIA of any one of embodiments 1- 28, comprising a human IgG2 Fc region; IgG2-IgG4 cross-subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2o). (32) The anti-TLIA of any one of embodiments 1-31, comprising a heavy chain Fc region comprising any one of SEQ ID NOS: 320-362. (33) The anti-TLIA of any one of embodiments 1-32, comprising a light chain constant region comprising SEQ ID NO: 319. (34) The anti-TLIA of any one of embodiments 1-33, comprising a light chain comprising a light chain framework comprising IGKV3-20*01, or a variant thereof, wherein the variant comprises between about 1 and about 2 substitutions, or between about 1 and about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. (35) The anti-TLIA antibody of embodiment 34, wherein X10 is L. (36) The anti-TLIA antibody of embodiment 34, wherein X10 is P. (37) The anti- TLIA antibody of any one of embodiments 34-36, wherein XI 1 is L. (38) The anti-TLIA antibody of any one of embodiments 34-36, wherein XI 1 is W.

[0126] In some embodiments, an anti-TLIA antibody comprises a heavy chain framework comprising SEQ ID NO: 302(XI VQLVQ SGAEVKKPGAS VKVSCKAS [HCDR1 ] W VX2QX3PGQGLEWX4G[HCDR2] RX5TX6TX7DTSTSTX8YX9ELSSLRSEDTAVYYC[HCDR3]WGQGTTVTVSS). In some cases, XI is Q. In some cases, XI = E. In some cases, X2 = R. In some cases, X2 = K. In some cases, X3 = A. In some cases, X3 = R. In some cases, X4 = M. In some cases, X4 = I.In some cases, X5 = V. In some cases, X5 = A. In some cases, X6 = M. In some cases, X6 =I. In some cases, X7 = R. In some cases, X7 = T. In some cases, X8 = V. In some cases, X8 = A. In some cases, X9 = M. In some cases, X9 = L. In some embodiments, XI is at position 1 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X2 is at position 45 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X3is at position 47 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X4 is at position 55 of IGHVl-46*02 as determined by Kabat numbering. In some embodiments, X5 is at position 78 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X6 is at position 80 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X7 is at position 82 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X8 is at position 89 of IGHV1 -46*02 as determined by Kabat numbering. In some embodiments, X9 is at position 91 of IGHV1- 46*02 as determined by Kabat numbering.

[0127] In one aspect, provided herein is another first embodiment of an anti-TLl A antibody comprising a heavy chain framework comprising IGHV1 -46*02, or a variant thereof, wherein the variant comprises between about 1 and about 9 amino acid substitutions, or between about 1 and about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from IGHVl-46*02 framework. Additional embodiments include: (2) The anti-TLl A of embodiment (1), wherein the heavy chain framework comprises SEQ ID NO: 302. (3) The anti-TLl A of embodiment 2, wherein XI = Q. (4) The anti-TLl A of embodiment 2, wherein XI = E. (5) The anti-TLl A of any one of embodiments 2-4, wherein X2 = R. (6) The anti-TLl A of any one of embodiments 2-4, wherein X2 = K. (7) The anti-TLl A of any one of embodiments 2-6, wherein X3 = A. (8) The anti-TLl A of any one of embodiments 2-6, wherein X3 = R. (9)The anti-TLIA of any one of embodiments 2-8, wherein X4 = M. (10) The anti-TLIA of any one of embodiments 2-8, wherein X4 = 1. (11) The anti-TLIA of any one of embodiments 2- 10, wherein X5 = V. (12) The anti-TLIA of any one of embodiments 2-10, wherein X5 = A. (13) The anti-TLIA of any one of embodiments 2-12, wherein X6 = M. (14) The anti-TLIA of any one of embodiments 2-12, wherein X6 = I. (15) The anti-TLIA of any one of embodiments 2-14, wherein X7 = R. (16) The anti-TLIA of any one of embodiments 2-14, wherein X7 = T. (17) The anti-TLIA of any one of embodiments 2-16, wherein X8 = V. (18) The anti-TLIA of any one of embodiments 2-16, wherein X8 = A. (19) The anti-TLIA of any one of embodiments 2-18, wherein X9 = M. (20) The anti-TLIA of any one of embodiments 2-4, wherein X9 = L. (21) The anti-TLIA of any one of embodiments 1-20, comprising antibody A. (22) The anti-TLIA of any one of embodiments 1-20, comprising antibody B. (23) The anti-TLIA of any one of embodiments 1-20, comprising antibody C. (24) The anti- TLIA of any one of embodiments 1-20, comprising antibody D. (25) The anti-TLIA of any one of embodiments 1-20, comprising antibody E. (26) The anti-TLIA of any one of embodiments 1-20, comprising antibody F. (27) The anti-TLIA of any one of embodiments1-20, comprising antibody G or I. (28) The anti-TLIA of any one of embodiments 1-20, comprising antibody H. (29) The anti-TLIA of any one of embodiments 1-28, comprising a human IgGl Fc region comprising: (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k) 331S, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V,238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440 A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. (30) The anti-TLIA of any one of embodiments 1-28, comprising a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P and L235E, or (b) S228P, F234A, and L235 A, per Rabat numbering. (31) The anti-TLIA of any one of embodiments 1-28, comprising a human IgG2 Fc region; IgG2-IgG4 cross-subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2o). (32) The anti-TLIA of any one of embodiments 1-31, comprising a heavy chain Fc region comprising any one of SEQ ID NOS: 320-362. (33) The anti-TLIA of any one of embodiments 1-32, comprising a light chain constant region comprising SEQ ID NO: 319. (34) The anti-TLIA of any one of embodiments 1-33, comprising a light chain comprising a light chain framework comprising IGRV3-20*01, or a variant thereof, wherein the variant comprises between about 1 and about 2 substitutions, or between about 1 and about 20 amino acid substitutions, or about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. (35) The anti-TLIA antibody ofembodiment 34, wherein X10 is L. (36) The anti-TLIA antibody of embodiment 34, wherein X10 is P. (37) The anti-TLIA antibody of any one of embodiments 34-36, wherein XI 1 is L. (38) The anti-TLIA antibody of any one of embodiments 34-36, wherein XI 1 is W.

[0128] In some embodiments, an anti-TLIA antibody comprises a light chain framework comprising SEQ ID NO: 303(EIVLTQSPGTLSLSPGERATLSC [LCDR1 ] W YQQKPGQ APRX 10X111 Y[LCDR2] GIPDR FSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK). In some cases, X10 is L. In some cases, XI 0 is P. In some cases, XI 1 is L. In some cases, XI 1 is W. In some embodiments, X10 is at position 54 of IGRV3-20*01 as determined by Rabat numbering. In some embodiments, XI 1 is at position 55 of IGRV3-20*01 as determined by Rabat numbering.

[0129] In some embodiments, an anti-TLIA antibody comprises a heavy chain framework comprising IGHVl-46*02. In some embodiments, an anti-TLIA antibody comprises a heavy chain framework comprising a variant of IGHV1 -46*02 comprising between about 1 and about 20 amino acid substitutions from SEQ ID NO: 316. In some embodiments, an anti-TLIA antibody comprises a heavy chain framework comprising a variant of IGHV1 -46*02 comprising between about 1 and about 9 amino acid substitutions from SEQ ID NO: 316. In some embodiments, an anti-TLIA antibody comprises a heavy chain framework comprising a variant of IGHVl-46*02 comprising about 1, 2, 3, 4, 5, 6, 7,8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from SEQ ID NO: 316 in the framework. In some cases, the heavy chain framework substitution comprises Q1E, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises R45R, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises A47R, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises M55I, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises V78A, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises M80I, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises R82T, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises V89A, as determined by Rabat numbering. In some cases, the heavy chain framework substitution comprises M91L, as determined by Rabat numbering.

[0130] In some embodiments, an anti-TLIA antibody comprises a light chain framework comprising IGRV3-20*01. In some embodiments, an anti-TLIA antibody comprises avariant of IGKV3-20*01 comprising between about 1 and about 20 amino acid substitutions from SEQ ID NO: 317. In some embodiments, an anti-TLIA antibody comprises a variant of IGKV3-20*01 comprising about 1 amino acid substitution from SEQ ID NO: 317. In some embodiments, an anti-TLIA antibody comprises a light chain framework comprising a variant of IGKV3-20*01 comprising about 2 amino acid substitutions from SEQ ID NO: 317. In some embodiments, an anti-TLIA antibody comprises a light chain framework comprising a variant of IGKV3-20*01 comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from SEQ ID NO: 317 in the framework. In some cases, the light chain framework substitution comprises Q1E, as determined by Kabat numbering. In some cases, the light chain framework substitution comprises R45K, as determined by Kabat numbering.

[0131] In some embodiments, an anti-TLIA antibody comprises a heavy chain FR1 as set forth by SEQ ID NO: 304. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR2 as set forth by SEQ ID NO: 305. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR2 as set forth by SEQ ID NO: 313. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR3 as set forth by SEQ ID NO: 306. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR3 as set forth by SEQ ID NO: 307. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR3 as set forth by SEQ ID NO: 314. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR3 as set forth by SEQ ID NO: 315. In some embodiments, an anti-TLIA antibody comprises a heavy chain FR4 as set forth by SEQ ID NO: 308. In some embodiments, an anti-TLIA antibody comprises a light chain FR1 as set forth by SEQ ID NO: 309. In some embodiments, an anti-TLIA antibody comprises a light chain FR2 as set forth by SEQ ID NO: 310. In some embodiments, an anti-TLIA antibody comprises a light chain FR3 as set forth by SEQ ID NO: 311. In some embodiments, an anti-TLIA antibody comprises a light chain FR4 as set forth by SEQ ID NO: 312.

[0132] In certain embodiments, an anti-TLIA antibody comprises the framework regions set forth in any one of the antibodies in Table 1, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the framework regions set forth in antibody A217, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the framework regions set forth in antibody A220, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLIA antibody comprises the framework regions set forth in antibodyA223, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A219, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A221, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A200, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A213, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A212, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A107, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A205, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A211, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A199, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A15, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A30, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A100, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A181, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A129, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A214, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regionsset forth in antibody A216, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A122, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A222, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A188, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A203, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A147, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A127, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A126, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A160, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A157, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A159, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A218, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A158, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A125, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A103, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A64, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises theframework regions set forth in antibody A67, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A138, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A68, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti- TLl A antibody comprises the framework regions set forth in antibody A94, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A110, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A197, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A112, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A169, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A173, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A179, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A148, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A115, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A149, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A134, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A113, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A151, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibodycomprises the framework regions set forth in antibody A96, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A132, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A196, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A172, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A75, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A174, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A109, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A198, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method. In certain embodiments, an anti-TLl A antibody comprises the framework regions set forth in antibody A170, wherein the framework regions are defined by the Kabat, Chothia, or IMGT method.Exemplary anti-TLIA Variable Regions

[0133] In one aspect, provided herein is an anti-TLIA antibody comprising a heavy chain variable region comprising an amino acid sequence at least about 85%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 101- 135; and a light chain variable region at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 201-206.

[0134] Further provided herein is a first embodiment of an anti-TLIA antibody comprising a heavy chain variable region and a light chain variable region. Non-limiting additional embodiments include: (Embodiment 2) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 101. (Embodiment 3) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101. (Embodiment 4) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acidsubstitutions or deletions as compared to SEQ ID NO: 101. (Embodiment 5) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 102. (Embodiment 6) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102. (Embodiment 7) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 102. (Embodiment 8) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 103. (Embodiment 9) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103. (Embodiment 10) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 103.

[0135] (Embodiment 11) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 104. (Embodiment 12) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104.(Embodiment 13) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 104. (Embodiment 14) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 105. (Embodiment 15) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105. (Embodiment 16) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 105. (Embodiment 17) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 106. (Embodiment 18) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106. (Embodiment 19) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 106. (Embodiment 20) The anti-TLIA antibody ofembodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 107. (Embodiment 21) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107. (Embodiment 22) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 107.

[0136] (Embodiment 23) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 108. (Embodiment 24) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108.(Embodiment 25) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 108. (Embodiment 26) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 109. (Embodiment 27) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109. (Embodiment 28) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 109. (Embodiment 29) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 110. (Embodiment 30) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110. (Embodiment 31) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 110. (Embodiment 32) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 111. (Embodiment 33) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111. (Embodiment 34) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 111. (Embodiment 35) The anti-TLIA antibody of embodiment 1, wherein the heavy chainvariable region comprises SEQ ID NO: 112. (Embodiment 36) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112. (Embodiment 37) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 112. (Embodiment 38) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 113. (Embodiment 39) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 113. (Embodiment 40) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 113.

[0137] (Embodiment 41) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 114. (Embodiment 42) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114.(Embodiment 43) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 114. (Embodiment 44) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 115. (Embodiment 45) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 115. (Embodiment 46) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 115. (Embodiment 47) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 116. (Embodiment 48) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116. (Embodiment 49) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 116. (Embodiment 50) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 117.(Embodiment 51) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117. (Embodiment 52) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 117.

[0138] (Embodiment 53) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 118. (Embodiment 54) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 118.(Embodiment 55) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 118. (Embodiment 56) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 119. (Embodiment 57) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119. (Embodiment 58) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 119. (Embodiment 59) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 120. (Embodiment 60) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 120. (Embodiment 61) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 120.

[0139] (Embodiment 62) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 121. (Embodiment 63) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121.(Embodiment 64) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 121. (Embodiment 65) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO:122. (Embodiment 66) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122. (Embodiment 67) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 122. (Embodiment 68) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 123. (Embodiment 69) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 123. (Embodiment 70) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 123. (Embodiment 71) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 124. (Embodiment 72) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 124. (Embodiment 73) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 124.

[0140] (Embodiment 74) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 125. (Embodiment 75) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 125.(Embodiment 76) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 125. (Embodiment 77) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 126. (Embodiment 78) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 126. (Embodiment 79) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 126. (Embodiment 80) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 127. (Embodiment 81) The anti-TLIA antibody ofembodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127. (Embodiment 82) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 127. (Embodiment 83) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 128. (Embodiment 84) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128. (Embodiment 85) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 128.

[0141] (Embodiment 86) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 129. (Embodiment 87) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 129.(Embodiment 88) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 129. (Embodiment 89) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 130. (Embodiment 90) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 130. (Embodiment 91) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 130. (Embodiment 92) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 131. (Embodiment 93) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 131. (Embodiment 94) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 131. (Embodiment 95) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 132. (Embodiment 96) The anti-TLl A antibody of embodiment 1, wherein the heavy chainvariable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 132. (Embodiment 97) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 132.

[0142] (Embodiment 98) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 133. (Embodiment 99) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 133.(Embodiment 100) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 133. (Embodiment 101) The anti- TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 134. (Embodiment 102) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134. (Embodiment 103) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 134. (Embodiment 104) The anti-TLl A antibody of embodiment 1, wherein the heavy chain variable region comprises SEQ ID NO: 135. (Embodiment 105) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135. (Embodiment 106) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 135.

[0143] (Embodiment 107) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises SEQ ID NO: 201. (Embodiment 108) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 109) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 201. (Embodiment 110) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises SEQ ID NO: 202. (Embodiment 111) Theanti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 112) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 202. (Embodiment 113) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises SEQ ID NO: 203. (Embodiment 114) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203. (Embodiment 115) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 203. (Embodiment 116) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises SEQ ID NO: 204. (Embodiment 117) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 118) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 204. (Embodiment 119) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises SEQ ID NO: 205. (Embodiment 120) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 121) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 205. (Embodiment 122) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises SEQ ID NO: 206. (Embodiment 123) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 206. (Embodiment 124) The anti-TLIA antibody of any one of embodiments 1-106, wherein the light chain variable region comprises a sequence having about 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions or deletions as compared to SEQ ID NO: 206.

[0144] (Embodiment 125) The anti-TLIA antibody of embodiment 1, comprising A217. (Embodiment 126) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 127) The anti-TLIA antibody of embodiment 1, comprising A220. (Embodiment 128) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 129) The anti-TLIA antibody of embodiment 1, comprising A223. (Embodiment 130) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 131) The anti-TLIA antibody of embodiment 1, comprising A219. (Embodiment 132) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 133) The anti-TLIA antibody of embodiment 1, comprising A221. (Embodiment 134) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.

[0145] (Embodiment 135) The anti-TLIA antibody of embodiment 1, comprising A200. (Embodiment 136) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 103, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 137) The anti-TLIA antibody of embodiment 1, comprising A213. (Embodiment 138) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 106, and the light chain variable region comprises a sequenceat least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 139) The anti-TLIA antibody of embodiment 1, comprising A212. (Embodiment 140) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 141) The anti-TLIA antibody of embodiment 1, comprising A107. (Embodiment 142) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 143) The anti-TLIA antibody of embodiment 1, comprising A205. (Embodiment 144) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202.

[0146] (Embodiment 145) The anti-TLIA antibody of embodiment 1, comprising A211. (Embodiment 146) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 147) The anti-TLIA antibody of embodiment 1, comprising A199. (Embodiment 148) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 109, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 149) The anti-TLIA antibody of embodiment 1, comprising A15. (Embodiment 150) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 203. (Embodiment 151) The anti-TLIA antibody of embodiment 1, comprising A30. (Embodiment 152) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or100% identical to SEQ ID NO: 108, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 153) The anti-TLIA antibody of embodiment 1, comprising A100. (Embodiment 154) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.

[0147] (Embodiment 155) The anti-TLIA antibody of embodiment 1, comprising A181. (Embodiment 156) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 107, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 157) The anti-TLIA antibody of embodiment 1, comprising A129. (Embodiment 158) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 110, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 159) The anti-TLIA antibody of embodiment 1, comprising A214. (Embodiment 160) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 111, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 161) The anti-TLIA antibody of embodiment 1, comprising A216. (Embodiment 162) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 112, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 163) The anti-TLIA antibody of embodiment 1, comprising A122. (Embodiment 164) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 113, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.

[0148] (Embodiment 165) The anti-TLIA antibody of embodiment 1, comprising A222. (Embodiment 166) The anti-TLIA antibody of embodiment 1, wherein the heavy chainvariable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 167) The anti-TLIA antibody of embodiment 1, comprising A188. (Embodiment 168) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 115, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 169) The anti-TLIA antibody of embodiment 1, comprising A203. (Embodiment 170) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 171) The anti-TLIA antibody of embodiment 1, comprising A147. (Embodiment 172) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 173) The anti-TLIA antibody of embodiment 1, comprising A127. (Embodiment 174) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 118, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204.

[0149] (Embodiment 175) The anti-TLIA antibody of embodiment 1, comprising A126. (Embodiment 176) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 114, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 177) The anti-TLIA antibody of embodiment 1, comprising A160. (Embodiment 178) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 102, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 179) The anti-TLIA antibody of embodiment 1, comprising A157.(Embodiment 180) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 104, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 181) The anti-TLIA antibody of embodiment 1, comprising A159. (Embodiment 182) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 183) The anti-TLIA antibody of embodiment 1, comprising A218. (Embodiment 184) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 119, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.

[0150] (Embodiment 185) The anti-TLIA antibody of embodiment 1, comprising A158. (Embodiment 186) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 101, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 187) The anti-TLIA antibody of embodiment 1, comprising A125. (Embodiment 188) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 105, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 189) The anti-TLIA antibody of embodiment 1, comprising A103. (Embodiment 190) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 120, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 191) The anti-TLIA antibody of embodiment 1, comprising A64. (Embodiment 192) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202.(Embodiment 193) The anti-TLIA antibody of embodiment 1, comprising A67. (Embodiment 194) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202.

[0151] (Embodiment 195) The anti-TLIA antibody of embodiment 1, comprising A138. (Embodiment 196) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 204. (Embodiment 197) The anti-TLIA antibody of embodiment 1, comprising A68. (Embodiment 198) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 123, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 199) The anti-TLIA antibody of embodiment 1, comprising A94. (Embodiment 200) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 124, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 202. (Embodiment 201) The anti-TLIA antibody of embodiment 1, comprising A110. (Embodiment 202) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 125, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 203) The anti-TLIA antibody of embodiment 1, comprising A197. (Embodiment 204) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 116, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205.

[0152] (Embodiment 205) The anti-TLIA antibody of embodiment 1, comprising A112. (Embodiment 206) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 117, and the light chain variable region comprises a sequenceat least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 207) The anti-TLIA antibody of embodiment 1, comprising A169. (Embodiment 208) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 126, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 209) The anti-TLIA antibody of embodiment 1, comprising A173. (Embodiment 210) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 211) The anti-TLIA antibody of embodiment 1, comprising A179. (Embodiment 212) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 127, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 213) The anti-TLIA antibody of embodiment 1, comprising A148. (Embodiment 214) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 121, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.

[0153] (Embodiment 215) The anti-TLIA antibody of embodiment 1, comprising A115. (Embodiment 216) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 217) The anti-TLIA antibody of embodiment 1, comprising A149. (Embodiment 218) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201. (Embodiment 219) The anti-TLIA antibody of embodiment 1, comprising A134. (Embodiment 220) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or100% identical to SEQ ID NO: 122, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 206. (Embodiment 221) The anti-TLIA antibody of embodiment 1, comprising A113. (Embodiment 222) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 124, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 223) The anti-TLIA antibody of embodiment 1, comprising A151. (Embodiment 224) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 124, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 201.

[0154] (Embodiment 225) The anti-TLIA antibody of embodiment 1, comprising A96. (Embodiment 226) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 227) The anti-TLIA antibody of embodiment 1, comprising A132. (Embodiment 228) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 128, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 206. (Embodiment 229) The anti-TLIA antibody of embodiment 1, comprising A196. (Embodiment 230) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 129, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 231) The anti-TLIA antibody of embodiment 1, comprising A172. (Embodiment 232) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 130, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 233) The anti-TLIA antibody of embodiment 1, comprising A75. (Embodiment 234) The anti-TLIA antibody of embodiment 1, wherein the heavy chainvariable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 131, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205.

[0155] (Embodiment 235) The anti-TLIA antibody of embodiment 1, comprising A174. (Embodiment 236) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 132, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 237) The anti-TLIA antibody of embodiment 1, comprising A109. (Embodiment 238) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 133, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 239) The anti-TLIA antibody of embodiment 1, comprising A198. (Embodiment 240) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 134, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 241) The anti-TLIA antibody of embodiment 1, comprising A170. (Embodiment 242) The anti-TLIA antibody of embodiment 1, wherein the heavy chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 135, and the light chain variable region comprises a sequence at least about 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to SEQ ID NO: 205. (Embodiment 243) The anti-TLIA antibody of embodiment 1, comprising A500. (Embodiment 244) The anti-TLIA antibody of embodiment 1, comprising A501.

[0156] (Embodiment 245) The anti-TLIA of any one of embodiments 1-244, comprising a human IgGl Fc region comprising: (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V,238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 271T, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc)304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440 A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. (Embodiment 246) The anti-TLIA of any one of embodiments 1-244, comprising a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P and L235E, or (b) S228P, F234A, and L235A, per Rabat numbering. (Embodiment 247) The anti-TLIA of any one of embodiments 1-244, comprising a human IgG2 Fc region; IgG2-IgG4 cross subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2o). (Embodiment 248) The anti-TLIA of any one of embodiments 1- 247, comprising a heavy chain Fc region comprising any one of SEQ ID NOS: 320-362. (Embodiment 249) The anti-TLIA of any one of embodiments 1-248, comprising a light chain constant region comprising SEQ ID NO: 319.

[0157] (Embodiment 250) The anti-TLIA of any one of embodiments 1-249, comprising at least about 80% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 251) The anti-TLIA of any one of embodiments 1- 250, comprising at least about 81%, at least about 82%, at least about 83%, or at least about 84% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 252) The anti-TLIA of any one of embodiments 1-251, comprising at least about 85% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 253) The anti-TLIA of any one of embodiments 1-252, comprising at least about 86%, at least about 87%, at least about 88%, or at least about 89% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 254) The anti-TLIA of any one of embodiments 1-253, comprising at least about 90% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 255) The anti-TLIA of any one of embodiments 1-254, comprising at least about 91%, at least about 92%, at leastabout 93%, or at least about 94% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 256) The anti-TLl A of any one of embodiments 1-255, comprising at least about 95% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 257) The anti-TLl A of any one of embodiments 1-256, comprising at least about 96%, at least about 97%, at least about 98%, or at least about 99% monomeric fraction as determined by the size exclusion chromatography method described herein.

[0158] (Embodiment 258) The anti-TLIA of any one of embodiments 1-257, comprising at least about 2 pg / mL expression as determined by the method disclosed herein. (Embodiment 259) The anti-TLIA of any one of embodiments 1-258, comprising between about 2 pg / mL and about 60 pg / mL expression as determined by the method disclosed herein. (Embodiment 260) The anti-TLIA of any one of embodiments 1-259, comprising between about 5 pg / mL and about 60 pg / mL expression as determined by the method disclosed herein. (Embodiment 261) The anti-TLIA of any one of embodiments 1-260, comprising between about 10 pg / mL and about 60 pg / mL expression as determined by the method disclosed herein. (Embodiment 262) The anti-TLIA of any one of embodiments 1- 261, comprising at least about 5 pg / mL expression as determined by the method disclosed herein. (Embodiment 263) The anti-TLIA of any one of embodiments 1-262, comprising at least about 10 pg / mL expression as determined by the method disclosed herein. (Embodiment 264) The anti-TLIA of any one of embodiments 1-263, comprising at least about 15 pg / mL expression as determined by the method disclosed herein. (Embodiment 265) The anti-TLIA of any one of embodiments 1-264, comprising at least about 20 pg / mL expression as determined by the method disclosed herein.Exemplary anti-TLIA Constant Regions

[0159] In some embodiments, one or more amino acid modifications may be introduced into the Fragment crystallizable (Fc) region of a human or humanized antibody, thereby generating an Fc region variant. An Fc region may comprise a C-terminal region of an immunoglobulin heavy chain that comprises a hinge region, CH2 domain, CH3 domain, or any combination thereof. As used herein, an Fc region includes native sequence Fc regions and variant Fc regions. The Fc region variant may comprise a human Fc region sequence ( e.g a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification ( e.g ., a substitution, addition, or deletion) at one or more amino acid positions. In an exemplary embodiment, the Fc region comprises any one of SEQ ID NOS: 320-362.

[0160] In some embodiments, antibodies of this disclosure have a reduced effector function as compared to a human IgG. Effector function refers to a biological event resulting from the interaction of an antibody Fc region with an Fc receptor or ligand. Non-limiting effector functions include Clq binding, complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody- dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex -mediated antigen uptake by antigen presenting cells, down regulation of cell surface receptors (e.g. B cell receptor), and B cell activation. In some cases, antibody-dependent cell-mediated cytotoxicity (ADCC) refers to a cell-mediated reaction in which nonspecific cytotoxic cells expressing Fc receptors (e.g., natural killer cells, neutrophils, macrophages) recognize bound antibody on a target cell, subsequently causing lysis of the target cell. In some cases, complement dependent cytotoxicity (CDC) refers to lysing of a target cells in the presence of complement, where the complement action pathway is initiated by the binding of Clq to antibody bound with the target.

[0161] Some Fc regions have a natural lack of effector function, and some Fc regions can comprise mutations that reduce effector functions. For instance, IgG4 has low ADCC and CDC activities and IgG2 has low ADCC activity.

[0162] The disclosure provides antibodies comprising Fc regions characterized by exhibiting ADCC that is reduced by at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70% or more as compared to an antibody comprising a non-variant Fc region, i.e., an antibody with the same sequence identity but for the substitution(s) that decrease ADCC (such as human IgGl, SEQ ID NO: 320). The disclosure provides antibodies comprising Fc regions characterized by exhibiting CDC that is reduced by at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70% or more as compared to an antibody comprising a non-variant Fc region, i.e., an antibody with the same sequence identity but for the substitution(s) that decrease CDC (such as human IgGl, SEQ ID NO: 320). In certain embodiments, the antibodies of this disclosure have reduced effector function as compared with human IgGl . Measurement of effector function may be performed as described in Example 3.

[0163] Non-limiting examples of Fc mutations in IgGl that may reduce ADCC and / or CDC include substitutions at one or more of positions: 231, 232, 234, 235, 236, 237, 238, 239, 264, 265, 267, 269, 270, 297, 299, 318, 320, 322, 325, 327, 328, 329, 330, and 331 in IgGl, where the numbering system of the constant region is that of the EU index as set forth by Kabat. In certain embodiments, the antibodies of this disclosure have reduced effectorfunction as compared with human IgGl.

[0164] In some embodiments, an antibody comprises an IgGl Fc region comprising an N297A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an N297Q substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an N297D substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an D265A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an S228P substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an L235A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an L237A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an L234A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an E233P substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an L234V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an C236 deletion, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising a P238A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an A327Q substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising a P329A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an P329G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an L235E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an P331S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an L234F substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising a 235G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 235Q substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 235Rsubstitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 235S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 236F substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 236R substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 237E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 237K substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 237N substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 237R substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238 A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 2381 substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238W substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 238Y substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 248A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254D substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 2541 substitution, according to the Kabatnumbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254N substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254P substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254Q substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254T substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 254V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 255N substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 256H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 256K substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 256R substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 256V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 264S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 265H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 265K substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 265S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 265Y substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 267G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 267H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 2671 substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 267K substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 268K substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 269N substitution, according to the Kabat numbering system. In someembodiments, an antibody comprises an IgGl Fc region comprising an 269Q substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 270A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 270G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 270M substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 270N substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 27 IT substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 272N substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 279F substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 279K substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 279L substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 292E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 292F substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 292G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 2921 substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 293 S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 301W substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 304E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 31 IE substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 311G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 311 S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 316F substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises anIgGl Fc region comprising an 327T substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 328V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 329Y substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 330R substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 339E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 339L substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 3431 substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 343 V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 373A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 373G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 373 S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 376E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 376W substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 376Y substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 380D substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 382D substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 382P substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 385P substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 424H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 424M substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 424V substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 4341substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 438G substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 439E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 439H substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 439Q substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440D substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440E substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440F substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440M substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440T Fc region substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising an 440V substitution, according to the Kabat numbering system.

[0165] In some embodiments, an antibody comprises a Fc region selected from the representative sequences disclosed in Table 3. In some embodiments, an antibody comprises an IgGl Fc region comprising E233P, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG4 Fc region comprising S228P and L235E. In some embodiments, an antibody comprises an IgGl Fc region comprising L235E, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A and L235A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A, L235A, and G237A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A, L235A, P329G, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234F, L235E, and P331S, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A, L235E, and G237A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A, L235E, G237A, and P33 IS, according tothe Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising L234A, L235A, and P329A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising G236R and L328R, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising G237A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising F241A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising V264A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising D265A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising D265A and N297A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising D265A and N297G, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising D270A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising N297A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising N297G, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising N297D, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising N297Q, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising P329A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising P329G, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising P329R, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising A330L, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising P331A, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgGl Fc region comprising P331S, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG2 Fc region. In some embodiments, an antibody comprises an IgG4 Fc region. In some embodiments, an antibody comprises an IgG4 Fc region comprising S228P, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG4 Fc region comprising S228P, F234A, and L235A, accordingto the Kabat numbering system. In some embodiments, an antibody comprises an IgG2-IgG4 cross-subclass (IgG2 / G4) Fc region. In some embodiments, an antibody comprises an IgG2- IgG3 cross-subclass Fc region. In some embodiments, an antibody comprises an IgG2 Fc region comprising H268Q, V309L, A330S, and P331S, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG2 Fc region comprising V234A, G237A, P238S, H268A, V309L, A330S, and P331S, according to the Kabat numbering system. In some embodiments, an antibody comprises a Fc region comprising high mannose glycosylation.

[0166] In some embodiments, an antibody comprises an IgG4 Fc region comprising a S228P substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG4 Fc region comprising an A330S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG4 Fc region comprising a P331S substitution, according to the Kabat numbering system.

[0167] In some embodiments, an antibody comprises an IgG2 Fc region comprising an A330S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG2 Fc region comprising an P331S substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG2 Fc region comprising an 234A substitution, according to the Kabat numbering system. In some embodiments, an antibody comprises an IgG2 Fc region comprising an 237A substitution, according to the Kabat numbering system.

[0168] In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising a sequence from Table 9B. In certain embodiments, an anti-TLl A described herein comprises a Fc region as shown in Table 14.Table 14. Exemplary Fc Mutations

[0169] In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 320 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 320. In certain embodiments, an anti- TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 321 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 321. In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 322 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 322. In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 323 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 323. In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 324 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 324. In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 325 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 325. In certain embodiments, an anti- TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 326 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 326. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 327 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 327. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 328 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 328. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 329 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 329. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 330 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 330. In certain embodiments, an anti- TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 331 or asequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 331. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 332 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 332. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 333 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 333. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 334 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 334. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 335 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 335. In certain embodiments, an anti- TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 336 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 336. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 337 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 337. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 338 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 338. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 339 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 339. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 340 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 340. In certain embodiments, an anti- TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 341 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 341. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 342 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 342. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 343 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 343. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 344 or a sequence at leastabout 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 344. In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 345 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 345. In certain embodiments, an anti- TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 346 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 346. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 347 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 347. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 348 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 348. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 349 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 349. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 350 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 350. In certain embodiments, an anti- TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 351 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 351. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 352 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 352. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 353 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 353. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 354 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 354. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 355 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 355. In certain embodiments, an anti- TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 356 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 356. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 357 or a sequence at least about 90%, 91%,92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 357. In certain embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 358 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 358. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 359 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 359. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 360 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 360. In certain embodiments, an anti- TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 361 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 361. In certain embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 362 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 362.

[0170] In some embodiments, the antibodies of this disclosure are variants that possess some but not all effector functions, which make it a desirable candidate for applications in which the half-life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.

[0171] In vitro and / or in vivo cytotoxicity assays can be conducted to confirm the reduction / depletion of CDC and / or ADCC activities. For example, Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity) but retains FcRn binding ability. Measurement of effector function may be performed as described in Example 3.

[0172] In some embodiments, antibodies are tested for binding to Fey receptors and complement Clq by ELISA. In some embodiments, antibodies are tested for the ability to activate primary human immune cells in vitro, for example, by assessing their ability to induce expression of activation markers.

[0173] In some embodiments, assessment of ADCC activity of an anti-TLIA antibody comprises adding the antibody to target cells in combination with immune effector cells, which may be activated by the antigen antibody complexes resulting in cytolysis of the target cell. Cytolysis may be detected by the release of label (e.g. radioactive substrates, fluorescent dyes or natural intracellular proteins) from the lysed cells. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells. Specific examples of in vitro ADCC assays are described in Wisecarver et ak, 1985 79:277-282; Bruggemann et al., 1987, J Exp Med 166:1351-1361; Wilkinson et al., 2001, J Immunol Methods 258:183-191; Patel et al., 1995 J Immunol Methods 184:29-38. Alternatively, or additionally, ADCC activity of the antibody of interest may be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., 1998, PNAS USA 95:652-656.

[0174] In some embodiments, antibodies comprising a Fc region herein exhibit decreased ADCC activities as compared to an unmodified antibody (e.g., an antibody with human IgGl). In some embodiments, the antibodies herein exhibit ADCC activities that are at least 2-fold, or at least 3-fold, or at least 5-fold or at least 10-fold or at least 50-fold or at least 100- fold less than that of an unmodified antibody. In some embodiments, antibodies herein exhibit ADCC activities that are reduced by at least 10%, or at least 20%, or by at least 30%, or by at least 40%, or by at least 50%, or by at least 60%, or by at least 70%, or by at least 80%, or by at least 90%, or by at least 100%, or by at least 200%, or by at least 300%, or by at least 400%, or by at least 500% relative to an unmodified antibody. In certain embodiments, antibodies herein have no detectable ADCC activity. In certain embodiments, the reduction and / or ablatement of ADCC activity may be attributed to the reduced affinity antibodies of the invention exhibit for Fc ligands and / or receptors.

[0175] In some embodiments, an assessment of complement activation, a CDC assay, may be performed as described in Gazzano-Santoro et al., 1996, J. Immunol. Methods, 202:163.

[0176] In some embodiments, antibodies comprising Fc regions described herein exhibit decreased affinities to Clq relative to an unmodified antibody (e.g., human IgGl). In some embodiments, antibodies herein exhibit affinities for Clq receptor that are at least 2 fold, or at least 3 fold, or at least 5 fold, or at least 7 fold, or at least 10 fold, or at least 20 fold, or at least 30 fold, or at least 40 fold, or at least 50 fold, or at least 60 fold, or at least 70 fold, or at least 80 fold, or at least 90 fold, or at least 100 fold, or at least 200 fold less than an unmodified antibody. In some embodiments, antibodies herein exhibit affinities for Clq that are at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or at least 5% less than an unmodified antibody. In some embodiments, antibodies herein exhibit affinities for Clq that are between about 100 nM to about 100 mM, or about 100 nM to about 10 pM, or about 100 nM to about 1 pM, or about 1 nM to about 100 pM, or about 10 nM to about 100 pM, or about 1 pM to about 100 pM, or about 10 pM to about 100 pM. In certain embodiments, antibodies herein exhibit affinities for Clq that are greater than 1 pM, greater than 5 pM, greater than 10 pM, greater than 25 pM, greater than 50 pM, or greater than 100 pM.

[0177] In some embodiments, antibodies comprising Fc regions described herein exhibit decreased CDC activities as compared to an unmodified antibody (e.g., human IgGl). In some embodiments, antibodies herein exhibit CDC activities that are at least 2-fold, or at least 3-fold, or at least 5-fold or at least 10-fold or at least 50-fold or at least 100-fold less than that of an unmodified antibody. In some embodiments, antibodies herein exhibit CDC activities that are reduced by at least 10%, or at least 20%, or by at least 30%, or by at least 40%, or by at least 50%, or by at least 60%, or by at least 70%, or by at least 80%, or by at least 90%, or by at least 100%, or by at least 200%, or by at least 300%, or by at least 400%, or by at least 500% relative to an unmodified antibody. In certain embodiments, antibodies herein exhibit no detectable CDC activities. In some embodiments, the reduction and / or ablatement of CDC activity may be attributed to the reduced affinity antibodies of the invention exhibit for Fc ligands and / or receptors.

[0178] Accordingly, further provided and described herein are anti-TLl A antibodies comprising a variant (e.g. harboring mutations) Fc region that reduce the cytotoxic response (e.g. ADCC or CDC) elicited by an anti-TLl A antibody. In some embodiments, an anti- TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 401 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 401. In some embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 402 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 402. In some embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 403 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 403. In some embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 404 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 404. In some embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 405 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 405. In some embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 406 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 406. In some embodiments, an anti-TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 407 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 407. In some embodiments, an anti- TLl A antibody described herein comprises a Fc region comprising SEQ ID NO: 408 or asequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 408. In some embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 409 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 409. In some embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 410 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 410. In some embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 411 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:411. In some embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 412 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 412. In some embodiments, an anti-TLIA antibody described herein comprises a Fc region comprising SEQ ID NO: 413 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 413.

[0179] By way of further example, in certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 501 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 501. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 502 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 502. In certain embodiments, an anti- TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 503 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 503. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 504 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 504. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 505 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 505. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 506 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 506. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 507 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 507. In certain embodiments, an anti-TL1 A antibody described herein comprises a heavy chain comprising SEQ ID NO: 508 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 508. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 509 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 509. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 510 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 510. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 511 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:511. In certain embodiments, an anti-TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 512 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 512. In certain embodiments, an anti- TLIA antibody described herein comprises a heavy chain comprising SEQ ID NO: 513 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 513. In certain embodiments, the heavy chain is paired with a light chain comprising SEQ ID NO: 514 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 514. In certain embodiments, the heavy chain is paired with the light chain variable region of SEQ ID NO: 514 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the light chain variable region of SEQ ID NO: 514.

[0180] In some embodiments, anti-TLIA described herein comprise a light chain constant region comprising SEQ ID NO: 319 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 319.Further Non-limiting Exemplary anti-TLIA Antibodies

[0181] In one aspect, provided herein is a first embodiment of an anti-TLIA antibody comprising a heavy chain comprising a HCDR1, a HCDR2, and a HCDR3, and a light chain comprising a LCDR1, a LCDR2, and a LCDR3. Non-limiting additional embodiments include: (Embodiment 2) The anti-TLIA antibody of embodiment 1, comprising a HCDR1 comprising SEQ ID NO: 1. (Embodiment 3) The anti-TLIA antibody of embodiment 1 or embodiment 2, comprising a HCDR2 comprising SEQ ID NO: 2. (Embodiment 4) The anti- TLIA antibody of embodiment 1 or embodiment 2, comprising a HCDR2 comprising SEQ ID NO: 3. (Embodiment 5) The anti-TLIA antibody of embodiment 1 or embodiment 2,comprising a HCDR2 comprising SEQ ID NO: 4. (Embodiment 6) The anti-TLl A antibody of embodiment 1 or embodiment 2, comprising a HCDR2 comprising SEQ ID NO: 5. (Embodiment 7) The anti-TLl A antibody of any one of embodiments 1-6, comprising a HCDR3 comprising SEQ ID NO: 6. (Embodiment 8) The anti-TLl A antibody of any one of embodiments 1-6, comprising aHCDR3 comprising SEQ ID NO: 7. (Embodiment 9) The anti-TLl A antibody of any one of embodiments 1-6, comprising aHCDR3 comprising SEQ ID NO: 8. (Embodiment 10) The anti-TLl A antibody of any one of embodiments 1-6, comprising a HCDR3 comprising SEQ ID NO: 9. (Embodiment 11) The anti-TLl A antibody of any one of embodiments 1-10, comprising a LCDR1 comprising SEQ ID NO: 10. (Embodiment 12) The anti-TLl A antibody of any one of embodiments 1-11, comprising a LCDR2 comprising SEQ ID NO: 11. (Embodiment 13) The anti-TLl A antibody of any one of embodiments 1-12, comprising a LCDR3 comprising SEQ ID NO: 12. (Embodiment 14) The anti-TLIA antibody of any one of embodiments 1-12, comprising a LCDR3 comprising SEQ ID NO: 13. (Embodiment 15) The anti-TLIA antibody of any one of embodiments 1-12, comprising a LCDR3 comprising SEQ ID NO: 14 or 15.

[0182] (Embodiment 16) The anti-TLIA antibody of any one of embodiments 1-15, comprising a heavy chain framework comprising IGHV1 -46*02. (Embodiment 17) The anti- TLIA antibody of any one of embodiments 1-15, comprising a heavy chain framework comprising a variant of IGHV1 -46*02 comprising between about 1 and about 20 amino acid substitutions from SEQ ID NO: 316. (Embodiment 18) The anti-TLIA antibody of any one of embodiments 1-15, comprising a heavy chain framework comprising a variant of IGHV1- 46*02 comprising between about 1 and about 9 amino acid substitutions from SEQ ID NO: 316. (Embodiment 19) The anti-TLIA antibody of any one of embodiments 1-15, comprising a heavy chain framework comprising a variant of IGHVl-46*02 comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from SEQ ID NO: 316 in the framework. (Embodiment 20) The anti-TLIA antibody of any one of embodiments 17-19, wherein the heavy chain framework substitution comprises Q1E, as determined by Rabat numbering. (Embodiment 21) The anti-TLIA antibody of any one of embodiments 17-20, wherein the heavy chain framework substitution comprises R45K, as determined by Rabat numbering. (Embodiment 22) The anti-TLIA antibody of any one of embodiments 17-21, wherein the heavy chain framework substitution comprises A47R, as determined by Rabat numbering. (Embodiment 23) The anti-TLIA antibody of any one of embodiments 17-22, wherein the heavy chain framework substitution comprises M55I, as determined by Rabat numbering. (Embodiment 24) The anti-TLIA antibody of any one ofembodiments 17-23, wherein the heavy chain framework substitution comprises V78A, as determined by Kabat numbering. (Embodiment 25) The anti-TLl A antibody of any one of embodiments 17-24, wherein the heavy chain framework substitution comprises M80I, as determined by Kabat numbering. (Embodiment 26) The anti-TLl A antibody of any one of embodiments 17-25, wherein the heavy chain framework substitution comprises R82T, as determined by Kabat numbering. (Embodiment 27) The anti-TLl A antibody of any one of embodiments 17-26, wherein the heavy chain framework substitution comprises V89A, as determined by Kabat numbering. (Embodiment 28) The anti-TLl A antibody of any one of embodiments 17-27, wherein the heavy chain framework substitution comprises M91L, as determined by Kabat numbering.

[0183] (Embodiment 29) The anti-TLIA antibody of any one of embodiments 1-15, comprising a heavy chain framework comprising SEQ ID NO: 301. (Embodiment 30) The anti-TLIA antibody of embodiment 29, wherein XI is Q. (Embodiment 31) The anti-TLIA of embodiment 29, wherein XI = E. (Embodiment 32) The anti-TLIA of any one of embodiments 29-31, wherein X2 = R. (Embodiment 33) The anti-TLIA of any one of embodiments 29-31, wherein X2 = K. (Embodiment 34) The anti-TLIA of any one of embodiments 29-33, wherein X3 = A. (Embodiment 35) The anti-TLIA of any one of embodiments 29-33, wherein X3 = R. (Embodiment 36) The anti-TLIA of any one of embodiments 29-35, wherein X4 = M. (Embodiment 37) The anti-TLIA of any one of embodiments 29-35, wherein X4 = I. (Embodiment 38) The anti-TLIA of any one of embodiments 29-37, wherein X5 = V. (Embodiment 39) The anti-TLIA of any one of embodiments 29-37, wherein X5 = A. (Embodiment 40) The anti-TLIA of any one of embodiments 29-39, wherein X6 = M. (Embodiment 41) The anti-TLIA of any one of embodiments 29-39, wherein X6 = I. (Embodiment 42) The anti-TLIA of any one of embodiments 29-41, wherein X7 = R. (Embodiment 43) The anti-TLIA of any one of embodiments 29-41, wherein X7 = T. (Embodiment 44) The anti-TLIA of any one of embodiments 29-43, wherein X8 = V. (Embodiment 45) The anti-TLIA of any one of embodiments 29-43, wherein X8 = A. (Embodiment 46) The anti-TLIA of any one of embodiments 29-45, wherein X9 = M. (Embodiment 47) The anti-TLIA of any one of embodiments 29-45, wherein X9 = L.

[0184] (Embodiment 48) The anti-TLIA antibody of any one of embodiments 1-15, comprising a heavy chain framework comprising SEQ ID NO: 302. (Embodiment 49) The anti-TLIA antibody of embodiment 48, wherein XI is Q. (Embodiment 50) The anti-TLIA of embodiment 48, wherein XI = E. (Embodiment 51) The anti-TLIA of any one ofembodiments 48-50, wherein X2 = R. (Embodiment 52) The anti-TLl A of any one of embodiments 48-50, wherein X2 = K. (Embodiment 53) The anti-TLl A of any one of embodiments 48-52, wherein X3 = A. (Embodiment 54) The anti-TLl A of any one of embodiments 48-52, wherein X3 = R. (Embodiment 55) The anti-TLl A of any one of embodiments 48-54, wherein X4 = M. (Embodiment 56) The anti-TLl A of any one of embodiments 48-54, wherein X4 = I. (Embodiment 57) The anti-TLl A of any one of embodiments 48-56, wherein X5 = V. (Embodiment 58) The anti-TLl A of any one of embodiments 48-56, wherein X5 = A. (Embodiment 59) The anti-TLl A of any one of embodiments 48-58, wherein X6 = M. (Embodiment 60) The anti-TLl A of any one of embodiments 48-58, wherein X6 = I. (Embodiment 61) The anti-TLl A of any one of embodiments 48-60, wherein X7 = R. (Embodiment 62) The anti-TLl A of any one of embodiments 48-60, wherein X7 = T. (Embodiment 63) The anti-TLl A of any one of embodiments 48-62, wherein X8 = V. (Embodiment 64) The anti-TLl A of any one of embodiments 48-62, wherein X8 = A. (Embodiment 65) The anti-TLl A of any one of embodiments 48-64, wherein X9 = M. (Embodiment 66) The anti-TLl A of any one of embodiments 48-64, wherein X9 = L.

[0185] (Embodiment 67) The anti-TLIA antibody of any one of embodiments 1-66, comprising a light chain framework comprising IGRV3-20*01. (Embodiment 68) The anti- TLIA antibody of any one of embodiments 1-66, comprising a light chain framework comprising a variant of IGRV3-20*01 comprising between about 1 and about 20 amino acid substitutions from SEQ ID NO: 317. (Embodiment 69) The anti-TLIA antibody of any one of embodiments 1-66, comprising a light chain framework comprising a variant of IGKV3- 20*01 comprising about 1 amino acid substitution from SEQ ID NO: 317. (Embodiment 70) The anti-TLIA antibody of any one of embodiments 1-66, comprising a light chain framework comprising a variant of IGKV3-20*01 comprising about 2 amino acid substitutions from SEQ ID NO: 317. (Embodiment 71) The anti-TLIA antibody of any one of embodiments 1-66, comprising a light chain framework comprising a variant of IGKV3- 20*01 comprising about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions from SEQ ID NO: 317 in the framework. (Embodiment 72) The anti-TLIA antibody of any one of embodiments 69-71, wherein the light chain framework substitution comprises Q1E, as determined by Rabat numbering. (Embodiment 73) The anti- TLIA antibody of any one of embodiments 69-72, wherein the light chain framework substitution comprises R45K, as determined by Rabat numbering.

[0186] (Embodiment 74) The anti-TLIA antibody of any one of embodiments 1-66,comprising a light chain comprising a light chain framework comprising SEQ ID NO: 303. (Embodiment 75) The anti-TLIA antibody of embodiment 74, wherein X10 is L. (Embodiment 76) The anti-TLIA antibody of embodiment 74, wherein X10 is P. (Embodiment 77) The anti-TLIA antibody of any one of embodiments 74-76, wherein XI 1 is L. (Embodiment 78) The anti-TLIA antibody of any one of embodiments 74-76, wherein XI 1 is W.

[0187] (Embodiment 79) The anti-TLIA of any one of embodiments 1-78, comprising a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234 A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S, 265Y, or 265A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd)311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss)440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. (Embodiment 80) The anti-TLIA of any one of embodiments 1-78, comprising a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P and L235E, or (b) S228P, F234A, and L235A, per Rabat numbering. (Embodiment 81) The anti-TLIA of any one of embodiments 1-78, comprising a human IgG2 Fc region; IgG2-IgG4 cross subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2a). (Embodiment 82) The anti-TLIA of any one of embodiments 1-81, comprising a heavy chain Fc region comprising any one of SEQ ID NOS: 320-362.(Embodiment 83) The anti-TLIA antibody of any one of embodiments 1-82, comprising a light chain constant region comprising SEQ ID NO: 319.

[0188] (Embodiment 84) The anti-TLIA antibody of any one of embodiments 1-83, comprising at least about 80% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 85) The anti-TLIA antibody of any one of embodiments 1-84, comprising at least about 81%, at least about 82%, at least about 83%, or at least about 84% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 86) The anti-TLIA antibody of any one of embodiments 1-85, comprising at least about 85% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 87) The anti- TLIA antibody of any one of embodiments 1-86, comprising at least about 86%, at least about 87%, at least about 88%, or at least about 89% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 88) The anti- TLIA antibody of any one of embodiments 1-87, comprising at least about 90% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 89) The anti-TLIA antibody of any one of embodiments 1-88, comprising at least about 91%, at least about 92%, at least about 93%, or at least about 94% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 90) The anti-TLIA antibody of any one of embodiments 1-89, comprising at least about 95% monomeric fraction as determined by the size exclusion chromatography method described herein. (Embodiment 91) The anti-TLIA antibody of any one of embodiments 1-90, comprising at least about 96%, at least about 97%, at least about 98%, or at least about 99% monomeric fraction as determined by the size exclusion chromatography method described herein.

[0189] (Embodiment 92) The anti-TLIA antibody of any one of embodiments 1-91, comprising at least about 2 pg / mL expression as determined by the method disclosed herein. (Embodiment 93) The anti-TLIA antibody of any one of embodiments 1-92, comprising between about 2 pg / mL and about 60 pg / mL expression as determined by the method disclosed herein. (Embodiment 94) The anti-TLIA antibody of any one of embodiments 1- 93, comprising between about 5 pg / mL and about 60 pg / mL expression as determined by the method disclosed herein. (Embodiment 95) The anti-TLIA antibody of any one of embodiments 1-94, comprising between about 10 pg / mL and about 60 pg / mL expression as determined by the method disclosed herein. (Embodiment 96) The anti-TLIA antibody of any one of embodiments 1-95, comprising at least about 5 pg / mL expression as determinedby the method disclosed herein. (Embodiment 97) The anti-TLl A antibody of any one of embodiments 1-96, comprising at least about 10 pg / mL expression as determined by the method disclosed herein. (Embodiment 98) The anti-TLl A antibody of any one of embodiments 1-97, comprising at least about 15 pg / mL expression as determined by the method disclosed herein. (Embodiment 99) The anti-TLl A antibody of any one of embodiments 1-98, comprising at least about 20 pg / mL expression as determined by the method disclosed herein. (Embodiment 100) The anti-TLIA antibody of any one of embodiments 1-91, comprising between about 2 pg / mL and about 50 pg / mL, between about 2 pg / mL and about 40 pg / mL, between about 2 pg / mL and about 30 pg / mL expression, between about 2 pg / mL and about 20 pg / mL, between about 5 pg / mL and about 50 pg / mL, between about 5 pg / mL and about 40 pg / mL, between about 5 pg / mL and about 30 pg / mL, between about 10 pg / mL and about 50 pg / mL, between about 10 pg / mL and about 40 pg / mL, or between about 10 pg / mL and about 30 pg / mL as determined by the method disclosed herein. (Embodiment 101) The anti-TLIA antibody of any one of embodiments 1- 91, comprising about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 pg / mL expression as determined by the method disclosed herein.

[0190] In some embodiments, an anti-TLIA antibody comprises antibody A. As used herein, antibody A comprises the CDRs of antibody A in Table 10. In some cases, antibody A comprises a heavy chain framework comprising SEQ ID NO: 301 (Embodiment X1VQLVQSGAEVKKPGASVKVSCKAS[HCDR1]WVX2QX3PGQGLEWX4G[HCDR2] RX5 TX6TX7DTST STX8 YX9ELS SLRSEDT AVYY C AR[HCDR3 ] WGQGTT VT V S S), wherein XI = Q or E, X2 = R or K, X3 = A or R, X4 = M or I, X5 = V or A, X6 = M or I, X7 = R or T, X8 = V or A, and X9 = M or L. In some cases, antibody A comprises a light chain framework comprising SEQ ID NO: 303 (EmbodimentEIVLT Q SPGTLSLSPGERATLSC [LCDR 1 ] W Y QQKPGQ APRX 10X11 IY[LCDR2] GIPDR F SGSGSGTDFTLTISRLEPEDF AVY Y C [LCDR3 ]FGGGTKLEIK), wherein X10 = L or P and XI 1 = L or W. In some cases, antibody A comprises a heavy chain variable region comprising human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework, wherein the modified human IGHV1 -46*02 framework has less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. In some cases, antibody A comprises a light chain variable region comprising human IGKV3-20 framework or a modified human IGKV3-20 framework, wherein the modified human IGKV3-20 framework has less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in theframework. In some cases, antibody A comprises a constant region comprising reduced ADCC and / or CDC as compared to IgGl. For instance, antibody A comprises a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k)33 IS, (1) 236F or 236R, (m) 238 A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G,267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x)27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 31 IE, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj)373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A,440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh)D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 320. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 321. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 322. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 323. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 324. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 325. In some cases, antibody A comprises a constant region comprising atleast about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 326. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 327. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 328. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 329. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 330. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 331. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 332. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 333. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 334. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 335. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 336. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 337. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 338. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 339. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 340. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%,or 100% identity to SEQ ID NO: 341. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 342. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 343. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 344. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 345. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 346. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 347. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 348. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 349. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 350. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 351. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 352. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 353. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 354. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 355. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 356. In some cases, antibody A comprises a constant regioncomprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 357. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 358. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 359. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 360. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 361. In some cases, antibody A comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 362. In some cases, antibody A comprises at least about 80%, 81%, 82%, 83%, 84%, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% monomeric fraction as measured by the size exclusion method described in Example 2. In some cases, antibody A is expressed from FreeStyle 293-F (e.g, ThermoFisher Scientific #R79007) cells at an expression level of about or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 5, 57, 58, 59 or 60 pg / mL as determined by the method described in Example 2. In some cases, antibody A is expressed from FreeStyle 293-F cells at an expression level of between about 2 pg / mL to about 60 pg / mL. In some cases, antibody A is expressed from FreeStyle 293-F cells at an expression level of between about 10 pg / mL to about 60 pg / mL. In some cases, antibody A comprises a viscosity less than about 30 mPa-s.In some cases, antibody A comprises a viscosity from about 4 mPa-s to about 30 mPa-s, or about 4, 5, 6, 7, 8, 9, 10. 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,29, 30 mPa-s. In some cases, antibody A is formulated in a solution having a concentration of about 10 mg / ml to about 170 mg / ml, with a viscosity less than about 30 mPa-s. In some cases, the formulation has a pH of about 5 to about 7.5.

[0191] In some embodiments, an anti-TLl A antibody comprises antibody B. As used herein, antibody B comprises the CDRs of antibody B in Table 10. In some cases, antibody B comprises a heavy chain framework comprising SEQ ID NO: 301(XI VQLVQ SGAEVKKPGAS VKVSCKAS [HCDR1 ] W VX2QX3PGQGLEWX4G[HCDR2] RX5 TX6TX7DTST STX8 YX9ELS SLRSEDT AVYY C AR[HCDR3 ] WGQGTT VT V S S),wherein XI = Q or E, X2 = R or K, X3 = A or R, X4 = M or I, X5 = V or A, X6 = M or I, X7 = R or T, X8 = V or A, and X9 = M or L. In some cases, antibody B comprises a light chain framework comprising SEQ ID NO: 303(EIVLTQSPGTLSLSPGERATLSC [LCDR1 ] W YQQKPGQ APRX 10X111 Y[LCDR2] GIPDR FSGSGSGTDFTLTISRLEPEDFAVYYC[LCDR3]FGGGTKLEIK), wherein X10 = L or P and XI 1 = L or W. In some cases, antibody B comprises a heavy chain variable region comprising human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework, wherein the modified human IGHV1 -46*02 framework has less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. In some cases, antibody B comprises a light chain variable region comprising human IGKV3-20 framework or a modified human IGKV3-20 framework, wherein the modified human IGKV3-20 framework has less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. In some cases, antibody B comprises a constant region comprising reduced ADCC and / or CDC as compared to IgGl. For instance, antibody B comprises a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k)33 IS, (1) 236F or 236R, (m) 238 A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G,267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x)27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 31 IE, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj)373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A,440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh)D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%,89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 320. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 321. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 322. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 323. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 324. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 325. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 326. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 327. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 328. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 329. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 330. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 331. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 332. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 333. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 334. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identityto SEQ ID NO: 335. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 336. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 337. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 338. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 339. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 340. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 341. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 342. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 343. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 344. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 345. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 346. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 347. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 348. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 349. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 350. In some cases, antibody B comprises a constant region comprising atleast about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 351. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 352. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 353. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 354. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 355. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 356. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 357. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 358. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 359. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 360. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 361. In some cases, antibody B comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 362. In some cases, antibody B comprises at least about 80%, 81%, 82%, 83%, 84%, 85%, 85%, 87%, 88%, 89%, 90%, 91%, 92%,93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% monomeric fraction as measured by the size exclusion method described in Example 2. In some cases, antibody B is expressed from FreeStyle 293-F cells at an expression level of about or at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 5, 57, 58, 59 or 60 pg / mL as determined by the method described in Example 2. In some cases, antibody B is expressed from FreeStyle 293-F cells at an expression level of between about 2 pg / mL toabout 60 pg / mL. In some cases, antibody B is expressed from FreeStyle 293 -F cells at an expression level of between about 10 pg / mL to about 60 pg / mL.

[0192] In some embodiments, an anti-TLl A antibody comprises antibody C. As used herein, antibody C comprises the CDRs of antibody C in Table 10. In some cases, antibody C comprises a heavy chain framework comprising SEQ ID NO: 301(XI VQLVQ SGAEVKKPGAS VKVSCKAS [HCDR1 ] W VX2QX3PGQGLEWX4G[HCDR2] RX5 TX6TX7DTST STX8 YX9ELS SLRSEDT AVYY C AR[HCDR3 ] WGQGTT VT V S S), wherein XI = Q or E, X2 = R or K, X3 = A or R, X4 = M or I, X5 = V or A, X6 = M or I, X7 = R or T, X8 = V or A, and X9 = M or L. In some cases, antibody C comprises a light chain framework comprising SEQ ID NO: 303(EIVLTQSPGTLSLSPGERATLSC [LCDR1 ] W YQQKPGQ APRX 10X111 Y[LCDR2] GIPDR F SGSGSGTDFTLTISRLEPEDF AVY Y C [LCDR3 ]FGGGTKLEIK), wherein X10 = L or P and XI 1 = L or W. In some cases, antibody C comprises a heavy chain variable region comprising human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework, wherein the modified human IGHV1 -46*02 framework has less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. In some cases, antibody C comprises a light chain variable region comprising human IGKV3-20 framework or a modified human IGKV3-20 framework, wherein the modified human IGKV3-20 framework has less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid substitutions in the framework. In some cases, antibody C comprises a constant region comprising reduced ADCC and / or CDC as compared to IgGl. For instance, antibody C comprises a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G, 329Y, or 329R (k)33 IS, (1) 236F or 236R, (m) 238 A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G,267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x)27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293S, (bb) 301W, (cc) 304E, (dd) 31 IE, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj)373 A, 373G, or 373S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A,440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A,(ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh)D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of (a) - (uu), per Rabat numbering. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 320. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 321. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 322. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 323. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 324. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 325. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 326. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 327. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 328. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%,90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 329. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 330. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 331. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99%, or 100% identity to SEQ ID NO: 332. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 333. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 334. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 335. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 336. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 337. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 338. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 339. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 340. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 341. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 342. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 343. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 344. In some cases, antibody C comprises a constant region comprising at least about 85%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 345. In so...

Claims

CLAIMSWHAT IS CLAIMED IS:

1. An antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable framework region comprising a human IGHV1 -46*02 framework or a modified human IGHV1 -46*02 framework, and a light chain variable framework region comprising a human IGKV3-20 framework or a modified human IGKV3-20 framework; wherein the heavy chain variable framework region and the light chain variable framework region collectively comprise less than 9 amino acid modifications from the human IGHVl-46*02 framework and the human IGKV3-20 framework.

2. The antibody or antigen binding fragment of claim 1, wherein the amino acid modification comprises: (a) a modification at amino acid position 47 in the heavy chain variable region; (b) a modification at amino acid position 45 in the heavy chain variable region; (c) a modification at amino acid position 55 in the heavy chain variable region; (d) a modification at amino acid position 78 in the heavy chain variable region; (e) a modification at amino acid position 80 in the heavy chain variable region; (f) a modification at amino acid position 82 in the heavy chain variable region; (g) a modification at amino acid position 89 in the heavy chain variable region; or (h) a modification at amino acid position 91 in the heavy chain variable region; per Kabat numbering; or a combination of two or more modifications selected from (a) to (h).

3. The antibody or antigen binding fragment of claim 2, wherein: (a) the amino acid modification is at position 47 in the heavy chain variable region, and the amino acid at position 47 is R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (b) the amino acid modification is at position 45 in the heavy chain variable region, and the amino acid at position 45 is A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (c) the amino acid modification is at position 55 in the heavy chain variable region, and the amino acid at position 55 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; (d) the amino acid modification is at position 78 in the heavy chain variable region, and the amino acid at position 78 is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y; (e) the amino acid modification is at position 80 in the heavy chain variable region, and the amino acid at position 80 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; (f) the amino acid modification is at position 82 in the heavy chain variable region, and the amino acid at position 82 is A, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, or V; (g) the amino acid modification is at position 89 in the heavy chain variable region, and the amino acid at position 89 is A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, or Y; or (h) theamino acid modification is at position 91 in the heavy chain variable region, and the amino acid at position 91 is A, R, N, D, C, Q, E, G, H, I, L, K, F, P, S, T, W, Y, or V; or a combination of two or more modifications selected from (a) to (h).

4. The antibody or antigen binding fragment of claim 1, wherein the amino acid modification comprises one or more of: A47R, R45K, M55I, V78A, M80I, R82T, V89A, M91L in the heavy chain variable region, per Rabat numbering.

5. The antibody or antigen binding fragment of claim 1 or claim 2, wherein the amino acid modification comprises: (a) a modification at amino acid position 54 in the light chain variable region; and / or (b) a modification at amino acid position 55 in the light chain variable region; per Rabat numbering.

6. The antibody or antigen binding fragment of claim 5, wherein: (a) the amino acid modification is at position 54 of the light chain variable region, and the amino acid at position 54 is A, R, N, D, C, Q, E, G, H, I, R, M, F, P, S, T, W, Y, or V; and / or (b) the amino acid modification is at position 55 of the light chain variable region, and the amino acid at position 55 is A, R, N, D, C, Q, E, G, H, I, R, M, F, P, S, T, W, Y, or V.

7. The antibody or antigen binding fragment of claim 5, wherein the amino acid modification comprises L54P and / or L55W in the light chain variable region, per Rabat numbering.

8. The antibody or antigen binding fragment of any one of claims 1-7, comprising a heavy chain CDR1 as set forth by SEQ ID NO: 1, a heavy chain CDR2 as set forth by any one of SEQ ID NOS: 2-5, a heavy chain CDR3 as set forth by any one of SEQ ID NOS: 6-9, a light chain CDR1 as set forth by SEQ ID NO: 10, a light chain CDR2 as set forth by SEQ ID NO: 11, and a light chain CDR3 as set forth by any one of SEQ ID NOS: 12-15.

9. The antibody or antigen binding fragment of any one of claims 1-8, comprising a heavy chain framework (FR) 1 as set forth by SEQ ID NO: 304, a heavy chain FR2 as set forth by SEQ ID NO: 305 or SEQ ID NO: 313, a heavy chain FR3 as set forth by any one of SEQ ID NOS: 306, 307, 314, or 315, a heavy chain FR4 as set forth by SEQ ID NO: 308, a light chain FR1 as set forth by SEQ ID NO: 309, a light chain FR2 as set forth by SEQ ID NO: 310, a light chain FR3 as set forth by SEQ ID NO: 311, or a light chain FR4 as set forth by SEQ ID NO: 312, or a combination thereof.

10. The antibody or antigen binding fragment of any one of claims 1-9, comprising a human IgGl Fc region comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279R, or 279L, (c) 228P, (d) 235 A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237R, 237N, or 237R, (f) 234 A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329A, 329G,329Y, or 329R (k) 331S, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V,238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265S,265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293 S,(bb) 301W, (cc) 304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 330R, (hh) 339E or 339L, (ii) 3431 or 343V, (jj) 373 A, 373G, or 373 S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq)438G, (rr) 439E, 439H, or 439Q, (ss) 440 A, 440D, 440E, 440F, 440M, 440T, or 440V,(tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P331S, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh) D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of two or more selected from (a) - (uu), per Rabat numbering.

11. The antibody or antigen binding fragment of any one of claims 1-9, comprising a human IgG4 Fc region.

12. The antibody or antigen binding fragment of any one of claims 1-9, comprising a Fc region comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362.

13. The antibody or antigen binding fragment of any one of claims 1-12, comprising at least about 80% monomeric fraction as determined by size exclusion chromatography.

14. The antibody or antigen binding fragment of any one of claims 1-13, expressing at least about 20 ug / ml total antibody, optionally about 20 ug / ml and 70 ug / mL total antibody.

15. An antibody or antigen binding fragment thereof that binds to TL1 A, comprising a heavy chain variable region comprising: (a) an HCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 1; (b) an HCDR2 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 2-5; and (c) an HCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 6-9; and the light chain variable region comprises: (d) an LCDR1 comprising an amino acid sequence set forth by SEQ ID NO: 10; (e) an LCDR2 comprising an amino acid sequence set forth by SEQ ID NO: 11; (f) an LCDR3 comprising an amino acid sequence set forth by any one of SEQ ID NOS: 12-15; and afragment crystallizable (Fc) region comprising reduced antibody-dependent cell-mediated cytotoxicity (ADCC) function as compared to human IgGl and / or reduced complement- dependent cytotoxicity (CDC) as compared to human IgGl .

16. The antibody of antigen binding fragment of claim 15, wherein the human IgGl comprises SEQ ID NO: 320.

17. The antibody of antigen binding fragment of claim 15 or claim 16, wherein the ADCC function of the Fc region comprising reduced ADCC is at least about 50% reduced as compared to human IgGl .

18. The antibody of antigen binding fragment of any one of claims 15-17 wherein the CDC function of the Fc region comprising reduced CDC is at least about 50% reduced as compared to human IgGl .

19. The antibody of antigen binding fragment of any one of claims 15-18, wherein the Fc region comprises a human IgGl comprising (a) 297A, 297Q, 297G, or 297D, (b) 279F, 279K, or 279L, (c) 228P, (d) 235A, 235E, 235G, 235Q, 235R, or 235S, (e) 237A, 237E, 237K, 237N, or 237R, (f) 234A, 234V, or 234F, (g) 233P, (h) 328A, (i) 327Q or 327T, (j) 329 A, 329G, 329Y, or 329R (k) 33 IS, (1) 236F or 236R, (m) 238A, 238E, 238G, 238H, 2381, 238V, 238W, or 238 Y, (n) 248 A, (o) 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, or 254V, (p) 255N, (q) 256H, 256K, 256R, or 256V, (r) 264S, (s) 265H, 265K, 265 S, 265 Y, or 265 A, (t) 267G, 267H, 2671, or 267K, (u) 268K, (v) 269N or 269Q, (w) 270 A, 270G, 270M, or 270N, (x) 27 IT, (y) 272N, (z) 292E, 292F, 292G, or 2921, (aa) 293 S, (bb) 301W, (cc) 304E, (dd) 311E, 311G, or 31 IS, (ee) 316F, (ff) 328V, (gg) 33 OR, (hh) 339E or 339L, (ii) 3431 or 343 V, (jj) 373 A, 373G, or 373 S, (kk) 376E, 376W, or 376Y, (11) 380D, (mm) 382D or 382P, (nn) 385P, (oo) 424H, 424M, or 424V, (pp) 4341, (qq) 438G, (rr) 439E, 439H, or 439Q, (ss) 440A, 440D, 440E, 440F, 440M, 440T, or 440V, (tt) E233P, (uu) L235E, (vv) L234A and L235A, (ww) L234A, L235A, and G237A, (xx) L234A, L235A, and P329G, (yy) L234F, L235E, and P33 IS, (zz) L234A, L235E, and G237A, (aaa), L234A, L235E, G237A, and P331S (bbb) L234A, L235A, G237A, P238S, H268A, A330S, and P331S (IgGlo), (ccc) L234A, L235A, and P329A, (ddd) G236R and L328R, (eee) G237A, (fff) F241A, (ggg) V264A, (hhh)D265A, (iii) D265A and N297A, (jjj) D265A and N297G, (kkk) D270A, (111) A330L, (mmm) P331 A or P331 S, or (nnn) any combination of two or more selected from (a) - (uu), per Rabat numbering.

20. The antibody of antigen binding fragment of any one of claims 15-18, comprising a (i) human IgG4 Fc region or (ii) a human IgG4 Fc region comprising (a) S228P, (b) S228P and L235E, or (c) S228P, F234A, and L235A, per Kabat numbering.

21. The antibody of antigen binding fragment of any one of claims 15-18, comprising a human IgG2 Fc region; IgG2-IgG4 cross-subclass Fc region; IgG2-IgG3 cross-subclass Fc region; IgG2 comprising H268Q, V309L, A330S, P331S (IgG2m4); or IgG2 comprising V234A, G237A, P238S, H268A, V309L, A330S, P331S (IgG2a).

22. The antibody of antigen binding fragment of any one of claims 15-18, wherein the Fc region comprises a human IgGl with a substitution selected from 329A, 329G, 329Y,33 IS, 236F, 236R, 238 A, 238E, 238G, 238H, 2381, 238V, 238W, 238 Y, 248 A, 254D, 254E, 254G, 254H, 2541, 254N, 254P, 254Q, 254T, 254V, 264S, 265H, 265K, 265 S, 265Y, 265A, 267G, 267H, 2671, 267K, 4341, 438G, 439E, 439H, 439Q, 440A, 440D, 440E, 440F, 440M, 440T, and 440V, per Kabat numbering.

23. The antibody or antigen binding fragment of any one of claims 15-18, comprising a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOS: 320-362.

24. The antibody or antigen binding fragment of any one of claims 15-18, wherein the Fc region comprises any one of SEQ ID NOs: 401-413 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 401-413.

25. The antibody or antigen binding fragment of any one of claims 15-18, wherein the heavy chain comprises any one of SEQ ID NOs: 501-513 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 501-513.

26. The antibody or antigen binding fragment of any one of claims 15-25, wherein the light chain comprises any one of SEQ ID NO: 514 or a sequence at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NO: 514.

27. The antibody or antigen binding fragment of any one of claims 15-26 comprising at least about 80% monomeric fraction as determined by size exclusion chromatography.

28. The antibody or antigen binding fragment of any one of claims 15-27, expressing at least about 20 ug / ml total antibody, optionally about 20 ug / ml and 70 ug / mL total antibody.

29. A method of treating inflammatory bowel disease (IBD) in a subject in need thereof, the method comprising administering to the subject an antibody or antigen binding fragment of any one of claims 1-28.

30. The method of claim 29, wherein the subject has fibrosis.

31. The method of claim 29, wherein the IBD comprises Crohn’s Disease.

32. The method of claim 29, wherein the IBD comprises ulcerative colitis.

33. A liquid composition comprising the antibody or antigen binding fragment of any one of claims 1-28, comprising a concentration of the antibody or antigen binding fragment of 10 mg / ml to 170 mg / ml.

34. A liquid composition comprising an antibody or antigen binding fragment thereof that binds to TL1 A, wherein the antibody or antigen binding fragment thereof is at a concentration of 10 mg / ml to 170 mg / ml.

35. The liquid composition of claim 33 or claim 34, comprising a pharmaceutically acceptable excipient.

36. The liquid composition of any one of claims 33-35, wherein the viscosity is from about 4 to about 30 mPa-s (millipascal-second (mPa s)).

37. The liquid composition of any one of claims 33-35, wherein the viscosity is from about 4 to about 10 mPa-s (millipascal-second (mPa s)).